DCP3 Series Acknowledgments

Disease Control Priorities, third edition (DCP3) compiles the global health knowledge of institutions and experts from around the world, a task that required the efforts of over 500 individuals, including volume editors, chapter authors, peer reviewers, advisory committee members, and research and staff assistants. For each of these contributions we convey our acknowledgment and appreciation. First and foremost, we would like to thank our 32 volume editors who provided the intellectual vision for their volumes based on years of professional work in their respective fields, and then dedicated long hours to reviewing each chapter, providing leadership and guidance to authors, and framing and writing the summary chapters. We also thank our chapter authors who collectively volunteered their time and expertise to writing over 170 comprehensive, evidence-based chapters.

We owe immense gratitude to the institutional sponsor of this effort: The Bill & Melinda Gates Foundation. The Foundation provided sole financial support of the Disease Control Priorities Network (DCPN). Many thanks to Program Officers Kathy Cahill, Philip Setel, Carol Medlin, Damian Walker and (currently) David Wilson for their thoughtful interactions, guidance, and encouragement over the life of the project. We also wish to thank Jaime Sepulveda for his longstanding support, including chairing the Advisory Committee for the second edition and, more recently, demonstrating his vision for DCP3 while he was a special advisor to the Gates Foundation. We are also grateful to the University of Washington’s Department of Global Health and successive chairs King Holmes and Judy Wasserheit for providing a home base for the DCP3 Secretariat, which included intellectual collaboration, logistical coordination, and administrative support.

We thank the many contractors and consultants who provided support to specific volumes in the form of economic analytical work, volume coordination, chapter drafting, and meeting organization: the Center for Disease Dynamics, Economics & Policy; Center for Chronic Disease Control; Centre for Global Health Research; Emory University; Evidence to Policy Initiative; Public Health Foundation of India; QURE Healthcare; University of California, San Francisco; University of Waterloo; University of Queensland; and the World Health Organization.

We are tremendously grateful for the wisdom and guidance provided by our advisory committee to the editors. Steered by Chair Anne Mills, the advisory committee ensures quality and intellectual rigor of the highest order for DCP3.

The National Academies of Sciences, Engineering, and Medicine, in collaboration with the Interacademy Medical Panel, coordinated the peer-review process for all DCP3 chapters. Patrick Kelley, Gillian Buckley, Megan Ginivan, Rachel Pittluck, and Tara Mainiero managed this effort and provided critical and substantive input.

World Bank Publishing provided exceptional guidance and support throughout the demanding production and design process. We would particularly like to thank Carlos Rossel, Mary Fisk, Nancy Lammers, Rumit Pancholi, Deborah Naylor, and Sherrie Brown for their diligence and expertise. Additionally, we thank Jose de Buerba, Mario Trubiano, Yulia Ivanova, and Chiamaka Osuagwu of the World Bank for providing professional counsel on communications and marketing strategies.

Several U.S. and international institutions contributed to the organization and execution of meetings that supported the preparation and dissemination of DCP3.
We would like to express our appreciation to the following institutions:

- University of Bergen, consultation on equity (June 2011)
- University of California, San Francisco, surgery volume consultations (April 2012, October 2013, February 2014)
- Institute of Medicine, first meeting of the Advisory Committee to the Editors (March 2013)
- Harvard Global Health Institute, consultation on policy measures to reduce incidence of noncommunicable diseases (July 2013)
- National Academy of Medicine, systems strengthening meeting (September 2013)
- Center for Disease Dynamics, Economics & Policy (Quality and Uptake meeting, September 2013; reproductive and maternal health volume consultation, November 2013)
- National Cancer Institute, cancer consultation (November 2013)
- Union for International Cancer Control, cancer consultation (November 2013, December 2014)
- Harvard T. H. Chan School of Public Health, economic evaluation consultation (September 2015)
- University of California, Berkeley School of Public Health, and Stanford Medical School, occupational and environmental health consultations (December 2015).

Carol Levin provided outstanding governance for cost and cost-effectiveness analysis. Stéphane Verguet added valuable guidance in applying and improving the extended cost-effectiveness analysis method. Elizabeth Brouwer, Kristen Danforth, Nazila Dabestani, Shane Murphy, Zachary Olson, Jinyuan Qi, and David Watkins provided exceptional research assistance and analytic assistance. Brianne Adderley ably managed the budget and project processes, while Jennifer Nguyen, Shamelle Richards, and Jennifer Grasso contributed exceptional project coordination support. The efforts of these individuals were absolutely critical to producing this series, and we are thankful for their commitment.
Volume and Series Editors

VOLUME EDITORS

Dorairaj Prabhakaran
Dorairaj Prabhakaran, MD, DM (Cardiology), MSc, FRCP, FNASC, is a cardiologist and epidemiologist, with special interest in genetic epidemiology. Until recently, he was Professor at All India Institute of Medical Sciences; he currently heads the Center for Chronic Disease Control and is Professor of Chronic Disease Epidemiology at the Public Health Foundation of India. He is the Head of the Center of Excellence–Center for Cardio-metabolic Risk Reduction in South Asia (CoE-CARRS) located in the Public Health Foundation of India and funded by the National Heart, Lung, and Blood Institute. He is also a consultant to the World Bank, the World Health Organization (WHO), and other international organizations and is a reviewer for several international and national journals. He is associate editor of Journal of Epidemiology and Community Health and member of the Editorial Advisory Board of Clinical Science. He has more than 100 publications in several high-impact journals, such as the New England Journal of Medicine, The Lancet, the Journal of the American Medical Association, and the Journal of American College of Cardiology.

Shuchi Anand
Shuchi Anand, MD, is an Instructor of Medicine at Stanford University School of Medicine, with a research focus on chronic kidney disease epidemiology and management in low-resource settings. She is a former Fogarty Scholar, and a current recipient of National Institute for Diabetes and Digestive and Kidney Diseases Career Development award. She is studying epidemiology and management of chronic kidney disease in urban India, dialysis practices in China, and the epidemic of chronic kidney disease in Sri Lanka.

Thomas A. Gaziano
Thomas A. Gaziano, MD, MSc, is jointly appointed to the Divisions of Cardiovascular Medicine and Social Medicine and Health Inequalities at Brigham & Women’s Hospital, Harvard Medical School, and the Department of Health Policy and Management, Harvard T. H. Chan School of Public Health, Cambridge, Massachusetts. He is certified as a Diplomate in Internal Medicine and Cardiovascular Diseases and has expertise in the treatment of cardiovascular diseases (CVD) in low- and middle-income countries, including the epidemiology and management of its risk factors. His research includes the development of decision analytic models to assess the cost-effectiveness of various screening, prevention, and management decisions. His international experience includes two years at Oxford University South Africa as the first Lancet International Fellow and four months in India evaluating CVD epidemiology and cost-effective strategies for its management. He has served as a consultant and author for the Disease Control Priorities Project organized by the World Bank; the WHO; and the Fogarty International Center, National Institutes of Health, and has been funded by the Bill & Melinda Gates Foundation.

Jean-Claude Mbanya
Jean-Claude Mbanya is Professor of Medicine and Endocrinology at the Faculty of Medicine and Biomedical Sciences, University of Yaoundé, Cameroon; Consultant Physician, Director of the Health in
Transition Research Group, and Director of the National Obesity Centre, University of Yaoundé, Cameroon; and Chief of the Endocrinology and Metabolic Diseases Unit at the Hospital Central in Yaoundé. Professor Mbanya served as President of the International Diabetes Federation (IDF) from 2009 to 2012. He was instrumental in the IDF-led Unite for Diabetes campaign, which led to the passage of the United Nations Day Resolution on Diabetes in December 2006. He now steers IDF strategic direction to encourage governments to implement policies for the treatment, care, and prevention of diabetes. His research mainly focuses on cultural diabetes-related factors, which are often unique to the Sub-Saharan African countries and communities he studies. His practice and research have largely contributed to increase the world’s awareness on diabetes in this region.

Rachel Nugent
Rachel Nugent is Vice President for Global Noncommunicable Diseases at RTI International. She was formerly a Research Associate Professor and Principal Investigator of the DCPN in the Department of Global Health at the University of Washington. Previously, she served as Deputy Director of Global Health at the Center for Global Development, Director of Health and Economics at the Population Reference Bureau, Program Director of Health and Economics Programs at the Fogarty International Center of the National Institutes of Health, and senior economist at the Food and Agriculture Organization of the United Nations. From 1991 to 1997, she was associate professor and department chair in economics at Pacific Lutheran University.

Yangfeng Wu
Yangfeng Wu is the Director of The George Institute, China. He is also the Executive Associate Director, Peking University Clinical Research Institute. A cardiovascular specialist, Professor Wu is responsible for the scientific program in China, which includes all areas of noncommunicable disease and injuries. Professor Wu has made valuable contributions to reduce the impact of cardiovascular disease in the region with his work at Fu Wai Hospital; the WHO Collaborating Center in Cardiovascular Disease Prevention, Control, and Research, China; and Peking University. While the director of the WHO Collaborating Center in Cardiovascular Disease Prevention, Control, and Research in China, he has reported on hypertension control in low- and middle-income countries, including reducing salt intake in populations.

SERIES EDITORS

Dean T. Jamison
Dean T. Jamison is an Emeritus Professor of Global Health at the University of Washington and an Emeritus Professor of Global Health Sciences at the University of California, San Francisco. He previously held academic appointments at Harvard University and the University of California, Los Angeles, and he was an economist on the staff of the World Bank, where he was lead author of the World Bank’s World Development Report 1993: Investing in Health. He was the lead editor of DCP2. He holds a PhD in economics from Harvard University and is an elected member of the Institute of Medicine of the U.S. National Academies. He recently served as Co-Chair and Study Director of The Lancet’s Commission on Investing in Health.

Rachel Nugent
See the list of Volume Editors.

Hellen Gelband
Hellen Gelband is an independent global health policy expert. Her work spans infectious disease, particularly malaria and antibiotic resistance, and noncommunicable disease policy, mainly in low- and middle-income countries. She has conducted policy studies at Resources for the Future, the Center for Disease Dynamics, Economics & Policy, the (former) Congressional Office of Technology Assessment, the Institute of Medicine of the U.S. National Academies, and a number of international organizations.

Susan Horton
Susan Horton is Professor at the University of Waterloo and holds the Centre for International Governance Innovation (CIGI) Chair in Global Health Economics in the Balsillie School of International Affairs there. She has consulted for the World Bank, the Asian Development Bank, several United Nations agencies, and the International Development Research Centre, among others, in work conducted in over 20 low- and middle-income countries. She led the work on nutrition for the Copenhagen Consensus in 2008, when micronutrients were ranked as the top development priority. She has served as associate provost of graduate
studies at the University of Waterloo, vice-president academic at Wilfrid Laurier University in Waterloo, and interim dean at the University of Toronto at Scarborough.

Prabhat Jha
Prabhat Jha is the founding director of the Centre for Global Health Research at St. Michael’s Hospital and holds Endowed and Canada Research Chairs in Global Health in the Dalla Lana School of Public Health at the University of Toronto. He is lead investigator of the Million Death Study in India, which quantifies the causes of death and key risk factors in over two million homes over a 14-year period. He is also Scientific Director of the Statistical Alliance for Vital Events, which aims to expand reliable measurement of causes of death worldwide. His research includes the epidemiology and economics of tobacco control worldwide.

Ramanan Laxminarayan
Ramanan Laxminarayan is Vice President for Research and Policy at the Public Health Foundation of India, and he directs the Center for Disease Dynamics, Economics & Policy in Washington, DC, and New Delhi. His research deals with the integration of epidemiological models of infectious diseases and drug resistance into the economic analysis of public health problems. He was one of the key architects of the Affordable Medicines Facility–malaria, a novel financing mechanism to improve access and delay resistance to antimalarial drugs. In 2012, he created the Immunization Technical Support Unit in India, which has been credited with improving immunization coverage in the country. He teaches at Princeton University.

Charles N. Mock
Charles N. Mock, MD, PhD, FACS, has training as both a trauma surgeon and an epidemiologist. He worked as a surgeon in Ghana for four years, including at a rural hospital (Berekum) and at the Kwame Nkrumah University of Science and Technology (Kumasi). In 2005–07, he served as Director of the University of Washington’s Harborview Injury Prevention and Research Center. In 2007–10, he worked at the WHO headquarters in Geneva, where he was responsible for developing the WHO’s trauma care activities. In 2010, he returned to his position as Professor of Surgery (with joint appointments as Professor of Epidemiology and Professor of Global Health) at the University of Washington. His main interests include the spectrum of injury control, especially as it pertains to low- and middle-income countries: surveillance, injury prevention, prehospital care, and hospital-based trauma care. He was President (2013–15) of the International Association for Trauma Surgery and Intensive Care.
Contributors

Alma Adler  
Department of Non-communicable Disease Epidemiology, London School of Hygiene & Tropical Medicine, London, United Kingdom

Ashkan Afshin  
Institute for Health Metrics and Evaluation, University of Washington, Seattle, Washington, United States

Vamadevan S. Ajay  
Centre for the Control of Chronic Conditions; Public Health Foundation of India, New Delhi, India

Mohammed K. Ali  
Rollins School of Public Health, Emory University, Atlanta, Georgia, United States

Shuchi Anand  
Stanford University School of Medicine, Stanford, California, United States

Eric Bateman  
Division of Pulmonology, Department of Medicine, University of Cape Town, South Africa

Janet Bettger  
Department of Orthopaedic Surgery, Duke University; Duke Clinical Research Institute; Duke Global Health Institute, Durham, North Carolina, United States

Robert O. Bonow  
Center for Cardiovascular Innovation, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, United States

Elizabeh Brouwer  
University of Washington, Seattle, Washington, United States

Gene Buhkman  
Department of Global Health & Social Medicine, Harvard University; Division of Cardiovascular Medicine, Harvard Medical School; Partners in Health, Boston, Massachusetts, United States

Fiona Bull  
Centre for the Built Environment and Health, The University of Western Australia, Crawley, Western Australia, Australia

Peter Burney  
National Heart & Lung Institute, Imperial College London, London, United Kingdom

Simon Capewell  
Institute of Psychology, Health and Society, University of Liverpool, Liverpool, United Kingdom

Juliana Chan  
MRC Epidemiology Unit, University of Cambridge, Cambridge, United Kingdom; Hong Kong Institute of Diabetes and Obesity; International Diabetes Federation Centre of Education; The Chinese University of Hong Kong–Prince of Wales Hospital, Hong Kong SAR, China

Eeshwar K. Chandrasekar  
Emory University School of Medicine, Atlanta, Georgia, United States

Jie Chen  
Shanghai Advanced Institute of Finance, Shanghai Jiao Tong University, Shanghai, China

Michael H. Criqui  
Division of Preventive Medicine, Department of Family Medicine and Public Health, University of California–San Diego School of Medicine, La Jolla, California, United States
John Dirks
Gairdner Foundation (Emeritus President);
Massey College, University of Toronto, Toronto,
Ontario, Canada

Chandrasagar B. Dugani
Department of Medicine, and Division of Cardiology,
Brigham and Women’s Hospital; Harvard Medical
School, Boston, Massachusetts, United States;
St. Michael’s Hospital; University of Toronto,
Toronto, Ontario, Canada

Michael Engelgau
Center for Translation Research and Implementation
Science, National Heart Lung and Blood Institute,
National Institutes of Health, Bethesda, Maryland,
United States

Meguid El Nahas
Sheffield Kidney Institute; Global Kidney Academy,
Sheffield, United Kingdom

Caroline H. D. Fall
MRC Lifecourse Epidemiology Unit, University of
Southampton, Southampton, United Kingdom

Valery Feigin
National Institute of for Stroke and Applied
Neurosciences, Auckland University of Technology,
Auckland, New Zealand

F. Gerald R. Fowkes
Usher Institute of Population Health Sciences and
Informatics, University of Edinburgh, Edinburgh,
United Kingdom

Thomas A. Gaziano
Harvard Medical School, Harvard T. H. Chan School of
Public Health; Brigham and Women’s Hospital, Boston,
Massachusetts, United States

Amanda Glassman
Center for Global Development, Washington, DC,
United States

Shifalika Goenka
Public Health Foundation of India, New Delhi, India

Rajeev Gupta
Fortis Escorts Hospital, New Delhi, India

Babar Hasan
Department of Paediatric and Child Health, The Aga
Khan University, Karachi, Pakistan

Fred Hersch
School of Public Health, Sydney Medical School,
University of Sydney, Sydney, Australia

Frank Hu
Harvard T. H. Chan School of Public Health, Boston,
Massachusetts, United States

Mark D. Huffman
Feinberg School of Medicine, Northwestern University,
Chicago, Illinois, United States

Samer Jabbour
Faculty of Health Sciences, American University of
Beirut, Beirut, Lebanon

Deborah Jarvis
National Heart & Lung Institute, Imperial College
London, London, United Kingdom

Panniyammakal Jeemon
Center for Control of Chronic Conditions, Public
Health Foundation of India, New Delhi, India

Rohina Joshi
The George Institute for Global Health; Faculty of
Medicine, University of Sydney, Sydney, Australia

Jemima H. Kamano
Department of Medicine, Moi University School of
Medicine; The Academic Model Providing Access to
Healthcare, Eldoret, Kenya

Andre Pascal Kengne
South African Medical Research Council, Tygerberg,
South Africa

Preeti Kudesia
Health, Nutrition, and Population Global Practice,
World Bank, Washington, DC, United States

R. Krishna Kumar
Department of Pediatric Cardiology, Amrita Institute
of Medical Sciences and Research Centre, Cochin, India

Kalyanaraman Kumaran
MRC Lifecourse Epidemiology Unit, University of
Southampton, Southampton, United Kingdom;
Epidemiology Research Unit, CSI Holdsworth
Memorial Hospital, Mysore, India

Estelle V. Lambert
Division of Exercise Science and Sports Medicine,
Department of Human Biology, Faculty of Health Sciences,
University of Cape Town, Cape Town, South Africa

Edward S. Lee
Keck School of Medicine, University of Southern
California, Los Angeles, California, United States

Carol Levin
Department of Global Health, University of
Washington, Seattle, Washington, United States
Chaoyun Li
Global Health Research Center, Duke Kunshan University, Kunshan, China

Rong Luo
The George Institute for Global Health, Peking University Health Science Center, Beijing, China

Matthew Magee
Georgia State University School of Public Health, Atlanta, Georgia, United States

Vasanti S. Malik
Department of Nutrition, Harvard T. H. Chan School of Public Health, Boston, Massachusetts, United States

J. Antonio Marin-Neto
Medical School of Ribeirão Preto, University of São Paulo, São Paulo, Brazil

Guy Marks
South Western Sydney Clinical School, University of New South Wales, Liverpool, New South Wales, Australia

Bongani Mayosi
Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa

Jean-Claude Mbanya
Faculty of Medicine and Biomedical Sciences, University of Yaoundé, Yaoundé, Cameroon

Helen McGuire
PATH, Seattle, Washington, United States

Renata Micha
Friedman School of Nutrition Science and Policy, Tufts University, Boston, Massachusetts, United States

J. Jaime Miranda
CRONICAS Center of Excellence for Chronic Diseases, Universidad Peruana Cayetano Heredia, Lima, Peru

Pablo Aschner Montoya
MRC Epidemiology Unit, University of Cambridge, Cambridge, United Kingdom; Javeriana University School of Medicine; San Ignacio University Hospital; Colombian Diabetes Association, Bogotá, Colombia

Andrew E. Moran
Division of General Medicine, Department of Medicine, Columbia University Medical Center, New York, New York, United States

Dariush Mozaffarian
Friedman School of Nutrition Science & Policy, Tufts University, Boston, Massachusetts, United States

Saraladevi Naicker
School of Clinical Medicine, University of the Witwatersrand, Johannesburg, South Africa

Nadraj G. Naidoo
University of Cape Town, Cape Town, South Africa

K. M. Venkat Narayan
Rollins School of Public Health, Emory University, Atlanta, Georgia, United States

Irina Nikolic
Division of Health, Nutrition, and Population Global Practice, World Bank, Washington, DC, United States

Rachel Nugent
Research Triangle Institute International, Research Triangle Park, North Carolina; Research Triangle Institute, Seattle, Washington, United States

Martin O’Donnell
National University of Ireland Galway, Galway, Ireland

Churchill Onen
Diabetes Association of Botswana, Gaborone, Botswana

Clive Osmond
MRC Lifecourse Epidemiology Unit, University of Southampton, Southampton General Hospital, Southampton, United Kingdom

Anushka Patel
University of Sydney, Sydney, Australia

Rogelio Perez-Padilla
National Institute of Respiratory Diseases of Mexico, Mexico City, Mexico

Neil Poulter
National Heart & Lung Institute, Imperial College London, London, United Kingdom

Dorairaj Prabhakaran
Centre for Chronic Disease Control; Public Health Foundation of India, New Delhi, India

Michael Pratt
National Center for Chronic Disease Prevention and Health Promotion, Centers for Disease Control and Prevention; Emory University, Atlanta, Georgia, United States

Miriam Rabkin
ICAP at Columbia, Mailman School of Public Health, Columbia University, New York, New York, United States

Vikram Rajan
World Bank, New Delhi, India
Anis Rassi
Anis Rassi Hospital, Goiânia, Brazil

Anis Rassi Jr.
Anis Rassi Hospital, Goiânia, Brazil

Ishita Rawal
Centre for Chronic Disease Control, New Delhi, India

Giuseppe Remuzzi
Istituto di Ricerche Farmacologiche Mario Negri, Centro Maria Astori; Bergamo, Italy

Miguel Riella
Evangelic School of Medicine; Evangelic University Hospital; Pro-Renal Brazil Foundation Curitiba, Parana, Brazil

Greg A. Roth
Division of Cardiology, Department of Medicine, School of Medicine, University of Washington, Seattle, Washington, United States

Ambuj Roy
All India Institute of Medical Sciences, New Delhi, India

Adolfo Rubinstein
South American Center of Excellence in Cardiovascular Health; Institute for Clinical Effectiveness and Health Policy; School of Medicine, University of Buenos Aires, Buenos Aires, Argentina

Yuna Sakuma
Center for Global Development, Washington, DC, United States

Uchechukwu K. A. Sampson
National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland, United States

Karen R. Siegel
Emory University, Atlanta, Georgia, United States

Karen Sliwa
Hatter Institute for Cardiovascular Research in Africa, University of Cape Town, Cape Town, South Africa

Marc Suhrcke
Centre for Health Economics, University of York, York, United Kingdom

Nikhil Tandon
All India Institute of Medical Sciences; Centre for Chronic Disease Control, New Delhi, India

Bernadette Thomas
Institute for Health Metrics and Evaluation, University of Washington, Seattle, Washington, United States

Claudia Vaca
Ministry of Health, Bogotá, Colombia

Rajesh Vedanthan
Icahn School of Medicine at Mount Sinai, New York, New York, United States

Stéphane Verguet
Department of Global Health and Population, Harvard T. H. Chan School of Public Health, Boston, Massachusetts, United States

David A. Watkins
Departments of Medicine and Global Health, University of Washington, Seattle, Washington, United States

Michael Webb
Stanford University, Palo Alto, California, United States

Mary Beth Weber
Emory Global Diabetes Research Center, Hubert Department of Global Health, Emory University, Atlanta, Georgia, United States

Laurie Whitsel
American Heart Association, Washington, DC, United States

Gary Wong
Prince of Wales Hospital, The Chinese University of Hong Kong, Shatin, Hong Kong SAR, China

Yangfeng Wu
The George Institute for Global Health, Peking University Health Science Center; Department of Epidemiology and Biostatistics, Peking University School of Public Health, Beijing, China

Lijing L. Yan
Global Health Research Center, Duke Kunshan University; The George Institute for Global Health, Peking University Health Science Center, Beijing, China

Clyde W. Yancy
Feinberg School of Medicine, Northwestern University, Chicago, Illinois, United States

Ping Zhang
Centers for Disease Control and Prevention, Atlanta, Georgia, United States

Dong Zhao
Department of Epidemiology, Beijing Anzhen Hospital, Capital Medical University, Beijing, China

Yishan Zhu
National School of Development, Peking University, Beijing, China
Advisory Committee to the Editors

Anne Mills, Chair  
Professor, London School of Hygiene & Tropical Medicine, London, United Kingdom

Olusoji Adeyi  
Director, Health, Nutrition and Population Global Practice, World Bank, Washington, DC, United States

Kesetebirhan Admasu  
Former Minister of Health, Addis Ababa, Ethiopia

George Alleyne  
Director Emeritus, Pan American Health Organization, Washington, DC, United States

Ala Alwan  
Regional Director Emeritus, World Health Organization, Regional Office for the Eastern Mediterranean, Cairo, Arab Republic of Egypt

Rifat Atun  
Professor, Global Health Systems, Harvard T. H. Chan School of Public Health, Boston, Massachusetts, United States

Zulfiqar Bhutta  
Chair, Division of Women and Child Health, Aga Khan University Hospital, Karachi, Pakistan

Agnes Binagwaho  
Former Minister of Health, Kigali, Rwanda

Mark Blecher  
Senior Health Advisor, South Africa Treasury Department, Cape Town, South Africa

Patricia Garcia  
Minister of Health, Lima, Peru

Roger Glass  
Director, Fogarty International Center, National Institutes of Health, Bethesda, Maryland, United States

Amanda Glassman  
Chief Operating Officer and Senior Fellow, Center for Global Development, Washington, DC, United States

Glenda Gray  
Executive Director, Perinatal HIV Research Unit, Chris Hani Baragwanath Hospital, Johannesburg, South Africa

Demissie Habte  
Chair of Board of Trustees, International Clinical Epidemiological Network, Addis Ababa, Ethiopia

Richard Horton  
Editor, The Lancet, London, United Kingdom

Edward Kirumira  
Dean, Faculty of Social Sciences, Makerere University, Kampala, Uganda

Peter Lachmann  
Professor, University of Cambridge, Cambridge, United Kingdom

Lai Meng Looi  
Professor, University of Malaya, Kuala Lumpur, Malaysia

Adel Mahmoud  
Senior Molecular Biologist, Princeton University, Princeton, New Jersey, United States

Anthony Measham  
World Bank (retired)

Carol Medlin  
Independent Consultant, Washington, DC, United States
Alvaro Moncayo  
Researcher, Universidad de los Andes, Bogotá, Colombia

Jaime Montoya  
Executive Director, Philippine Council for Health Research and Development, Taguig City, the Philippines

Ole Norheim  
Professor, Department of Global Public Health and Primary Care, University of Bergen, Bergen, Norway

Folashade Omokhodion  
Professor, University College Hospital, Ibadan, Nigeria

Toby Ord  
President, Giving What We Can, Oxford, United Kingdom

K. Srinath Reddy  
President, Public Health Foundation of India, New Delhi, India

Sevket Ruacan  
Dean, Koç University School of Medicine, Istanbul, Turkey

Jaime Sepúlveda  
Executive Director, Global Health Sciences, University of California, San Francisco, San Francisco, California, United States

Richard Skolnik  
Yale University School of Public Health (retired)

Stephen Tollman  
Professor, University of Witwatersrand, Johannesburg, South Africa

Jürgen Unutzer  
Professor, Department of Psychiatry, University of Washington, Seattle, Washington, United States

Damian Walker  
Deputy Director of Data and Analytics, Bill & Melinda Gates Foundation, Seattle, Washington, United States

Ngaire Woods  
Director, Global Economic Governance Program, Oxford University, Oxford, United Kingdom

Nopadol Wora-Urai  
Professor, Department of Surgery, Phramongkutklao Hospital, Bangkok, Thailand

Kun Zhao  
Researcher, China National Health Development Research Center, Beijing, China
Reviewers

Olusoji Adeyi
Director, Health, Nutrition, and Population Global Practice, World Bank, Washington, DC, United States

Kamel Ajlouni
The National Center for Diabetes, Endocrinology and Genetics; The University of Jordan, Amman, Jordan

Wael K. Al-Delaimy
University of California–San Diego, La Jolla, California, United States

Valter Cordeiro Barbosa Filho
Research Centre in Physical Activity and Health, Federal University of Santa Catarina, Florianópolis, Brazil

Robert Beaglehole
International Public Health Consultants, Auckland, New Zealand

Digambar Behera
Department of Pulmonary Medicine, Postgraduate Institute of Medical Education & Research; WHO Collaborating Centre for Research and Capacity Building in Chronic Respiratory Diseases, Chandigarh, India

Liwei Chen
Clemson University, Clemson, South Carolina, United States

Valentin Fuster
The Mount Sinai Medical Hospital; Mount Sinai Heart; Icahn School of Medicine at Mount Sinai, New York, New York, United States

Guillermo García-García
Hospital Civil de Guadalajara “Fray Antonio Alcalde,” University of Guadalajara Health Sciences Center, Guadalajara, Mexico

Scott Kahan
National Center for Weight and Wellness, Washington, DC, United States; Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, United States

Jonathan Kaltman
National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland, United States

Eduardo M. Krieger
Heart Institute, Medical School of the University of São Paulo (InCor-FMUSP), São Paulo, Brazil

Harriet V. Kuhnlein
Centre for Indigenous Peoples’ Nutrition and Environment and School of Dietetics and Human Nutrition, McGill University, Montreal, Canada

Anuradha Lala
Icahn School of Medicine at Mount Sinai; The Zena and Michael A. Wiener Cardiovascular Institute, Mount Sinai Hospital, New York, New York, United States

Naomi Levitt
University of Cape Town; Chronic Disease Initiative for Africa, Cape Town, South Africa

Carlos Mendoza Montano
Institute of Nutrition of Central America and Panama (INCAP); INCAP Research Center for the Prevention of Chronic Diseases, Guatemala City, Guatemala

George A. Mensah
National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland, United States

Andrew J. Mirelman
Centre for Health Economics, University of York, York, United Kingdom
Monica L. Mispireta
School of Nursing, Idaho State University, Pocatello, Idaho, United States

Jorge A. Motta
National Secretary Science, Technology and Innovation, Panama City, Panama

Jagat Narula
Journal of the American College of Cardiology, Washington, DC, United States; Arnhold Institute for Global Health at Mount Sinai; Icahn School of Medicine at Mount Sinai; Mount Sinai West and Mount Sinai St. Luke’s Hospitals, New York, New York, United States

Frida Ngalesoni
University of Bergen, Bergen, Norway

Ole Frithjof Norheim
University of Bergen, Bergen, Norway

Pekka Puska
National Institute for Health and Welfare (THL), Helsinki, Finland

Cristina Rabadan-Diehl
Office of the Americas, Office of Global Affairs, United States Department of Health and Human Services, Washington, DC, United States

K. Srinath Reddy
Public Health Foundation of India, New Delhi, India

Rebecca Reynolds
University of Edinburgh, Edinburgh, United Kingdom

Jonathan M. Samet
Keck School of Medicine, University of Southern California (USC); USC Institute for Global Health, Los Angeles, California, United States

John W. Stanifer
Duke University; Duke Clinical Research Institute; Duke Global Health Institute, Durham, North Carolina, United States

Nigel Unwin
Chronic Disease Research Centre, University of the West Indies, Barbados; MRC Epidemiology Unit, Cambridge University, Cambridge, United Kingdom

Martin Veller
University of the Witwatersrand, Johannesburg, South Africa

S. Goya Wannamethee
University College London Medical School, London, United Kingdom

Kremlin Wickramasinghe
Nuffield Department of Population Health, University of Oxford, Oxford, United Kingdom

Edwina H. Yeung
Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, Maryland, United States
Policy Forum Participants

The following individuals provided valuable insights to improve this volume’s key findings through participation in the Disease Control Priorities-World Health Organization, Eastern Mediterranean Regional Office policy forum on Cardiovascular Disease and Diabetes, in Geneva, Switzerland, on November 14, 2015. The forum was organized by Dr. Ala Alwan, Regional Director, World Health Organization, and member of the DCP3 Advisory Committee to the Editors.

Ala Alwan
Regional Director Emeritus, World Health Organization Regional Office for the Eastern Mediterranean, Cairo, Arab Republic of Egypt

Fawzi Amin
Secretary General, Bahrain Red Crescent Society; Former Director General of Primary Health Care and Assistant Undersecretary, Ministry of Health, Manama, Bahrain

Walid Ammar
Director General, Ministry of Public Health, Beirut, Lebanon

Karim Aoun
Director General, Ministry of Health, Tunisia; Professor in Parasitology, Medical School of Tunis, Tunis, Tunisia

Nooshin Mohd Bazargani
Deputy Head of Dubai Heart Centre, Dubai, United Arab Emirates; Board Member of World Heart Federation, Geneva, Switzerland; Chair, CVD Prevention Group of Emirates Cardiac Society, Abu Dhabi, United Arab Emirates

Suraya Dalil
Permanent Representative of the Government of the Islamic Republic of Afghanistan to the United Nations, Geneva, Switzerland; Former Minister of Health, Kabul, Afghanistan

Reida M. A. Elaokley
Minister of Health, Ministry of Health, El-Beida, Libya

Hassen Ghannem
Director, Tunisia Center of Excellence to Combat Chronic Diseases, Department of Epidemiology, University Hospital Farhat Hached, Sousse, Tunisia

Assad Hafeez
Director General of Health, Ministry of National Health Services, Regulation, and Coordination, Islamabad, Pakistan

Ali bin Talib Al Hinai
Undersecretary for Planning, Ministry of Health, Muscat, Oman

Didier Houssin
President, High Council for the Evaluation of Research and Higher Education, Paris, France; Former Director General for Health, Ministry of Health, Paris, France

Azhar Mahmoud Kayani
Consultant Cardiologist, Army Medical College, Rawalpindi, Pakistan

Sa’ad Kharabsheh
Former Minister of Health, Amman, Jordan
Bagher Ardeshir Larijani
Deputy Minister for Education; Head of High Level NCD Council, Ministry of Health and Medical Education, Tehran, Islamic Republic of Iran

Pekka Puska
Former Director General, The National Institute for Health and Welfare, Helsinki, Finland

Ali Faraj Al-Qaraghuli
Senior Consultant Cardiologist, Al Oyoun Hospital, Amman, Jordan

Junaid Razzak
Director, Telemedicine Programme and Senior Advisor Global Health, Department of Emergency Medicine, Johns Hopkins University School of Medicine; Department of International Health, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, Maryland, United States; Visiting Faculty, Department of Emergency Medicine, Aga Khan University, Karachi, Pakistan

Qasim Bin Ahmad Al Salimi
Director General, The Royal Hospital, Muscat, Oman

Amirhossein Takian
Deputy Acting Minister for International Affairs, Ministry of Health and Medical Education, Tehran, Islamic Republic of Iran

Mohammed Hamad J. Al-Thani
Director of Public Health, Department of Public Health, Ministry of Public Health, Doha, Qatar
Index

Boxes, figures, maps, notes, and tables are indicated by b, f, m, n, and t following page numbers.

A
abdominal obesity, 28–29. See also obesity/overweight
Academia de Cidade (Brazil), 90b
Academic Model Providing Access to Healthcare (AMPATH), 331
ACE inhibitors. See angiotensin-converting enzyme (ACE) inhibitors
ACE Obesity Study, 127–29, 128t
acute kidney injury (AKI), 15, 178, 235–39, 237b, 242, 383
acute rheumatic fever (ARF), 197–200, 357
ADA. See American Diabetes Association
adherence to treatment
chronic respiratory diseases, 270, 272–73
community-based care and, 315, 321
cost-effectiveness of interventions and, 358
costs and, 356–58
diabetes, 218, 223
heart failure, 182, 186
hypertension, 163, 395, 397
integrated care and, 296–97
ischemic heart disease, 142, 144, 146
obesity interventions, 126
rheumatic heart disease, 198, 202
stroke, 160
Adler, Alma, 389
adolescence, BMI in, 42–43
Africa. See also specific countries
congenital heart disease in, 194
cost-effectiveness of interventions in, 353
diabetes in, 211, 216
diet and nutrition in, 106
heart failure in, 175, 185
ischemic heart disease in, 138–40, 142–43
kidney disease in, 236
obesity/overweight in, 120
priority-setting for treatments in, 379
quality of care in, 338, 340, 342
rheumatic heart disease in, 200
tobacco use in, 68
Afshin, Ashkan, 101
Agita São Paulo (Brazil), 90b
AIDS. See HIV/AIDS
Ajay, Vamadevan S., 23, 287
AKI. See acute kidney injury
Ali, Mohammed K., 209, 287
Allen, K., 110
Alzheimer’s disease, 64–65
American College of Cardiology, 174b
American College of Sports Medicine, 89
American Diabetes Association (ADA), 85, 214–15, 217
American Heart Association, 162, 174b
American Stroke Association, 162
AMPATH (Academic Model Providing Access to Healthcare), 331
Amrita Institute of Medical Sciences (India), 196
Anand, Shuchi, 1, 235
angina, 136
angiotensin receptor blockers (ARBs), 7, 15, 142, 145, 178, 215, 219, 222, 242–43, 247, 357, 391–92
antibiotics, 237, 274–76
anticoagulation therapies, 164–65, 179, 186
anti hypertensive treatments, 163, 165, 186, 393
antiplatelet therapy, 166, 393
aortic artery disease, 66
ARBs. See angiotensin receptor blockers
ARF. See acute rheumatic fever
Argentina
Chagas disease in, 204
cost-effectiveness of interventions in, 353, 359
diet and nutrition in, 108, 110
heart failure in, 184
ischemic heart disease in, 141, 147
priority-setting for treatments in, 378–83
quality of care in, 342
stroke in, 165
Armour, T. A., 314
arrhythmia, 64, 66, 178
Asaria, P., 110
aspirin, 141–46, 164, 166, 179, 185, 254, 329, 333, 336, 341, 357–59, 375, 389, 393, 395
asthma
assessment, 271–72
barriers to care, 272–73
burden of disease, 263–65
community-based care, 307–8
diagnosis, 271
management of, 272, 277, 308, 310
mortality and morbidity trends, 27
pharmacological management, 272
prevention, 269
risk factors, 263–65
symptoms, 27, 271–72
atenolol, 8, 142, 178, 392–93
atherosclerosis, 58b
atherothrombosis, 58b
atrial fibrillation, 64, 66, 160–64, 179, 197, 398
Australia
Chagas disease in, 203
chronic respiratory diseases in, 264
community-based care in, 305, 311
diabetes in, 216
diet and nutrition in, 106
ischemic heart disease in, 144, 146
obesity/overweight in, 126–27, 129
physical activity in, 87–88
B
Bakshi, K. D., 196
Bangladesh
cardiometabolic disease in, 46–47
community-based care in, 310
cost-effectiveness of interventions in, 356
hypertension in, 397
bariatric surgery, 127
Barker, D. J. P., 37, 39
Barthel Index, 168, 316
Bateman, Eric, 263
Belarus
breastfeeding promotion in, 47
ischemic heart disease in, 138
Bettger, Janet, 157
bidi smoking, 68. See also tobacco use
birth weight
cardiometabolic disease and, 37–40, 43–46, 48
low birth weight, 30–31, 37, 39, 43–45, 241, 267–68
bisphenol, 44
blood pressure (BP)
cardiometabolic disease and, 39–40, 42, 44–47
cost-effectiveness of interventions, 356–58
diabetes and, 214, 216–17
integrated care and, 295, 297
kidney disease and, 243–44
management of, 389, 391–92, 395, 397–98
physical activity and, 84–85, 91
quality of care and, 330, 336–38, 340
as risk factor, 28–30
stroke and, 161, 163–65, 166
tobacco use and, 60, 62–63, 66, 70
BMI. See body mass index
body fat. See also obesity/overweight
cardiometabolic disease and, 40–41
obesity/overweight and, 117–18
physical activity and, 91
body mass index (BMI)
cardiometabolic disease and, 37, 39, 41–43, 47–48
chronic respiratory diseases and, 264
diet and, 104
integrated care and, 292
obesity/overweight and, 117–19, 123, 128
physical activity and, 83–86
priority-setting for treatments, 385
Bonow, Robert O., 135
Boston University, 241b
BP. See blood pressure
Brazil
Chagas disease in, 204
chronic respiratory diseases in, 278
community-based care in, 314
community-based physical activity programs in, 90b
cost-effectiveness of interventions in, 16, 353, 359–60
diabetes in, 10, 213
diet and nutrition in, 110
heart failure in, 184
ischemic heart disease in, 139, 141–42
kidney disease in, 236, 240, 244
obesity/overweight in, 118, 120–21, 124–25, 127, 130
physical activity in, 14, 82, 87, 89, 92–93
priority-setting for treatments in, 378–80, 382, 384
quality of care in, 332, 342
rheumatic heart disease in, 201
stroke in, 163
tobacco use in, 68
breastfeeding, 44, 47
bronchiectasis, 268–69, 276
bronchodilators, 274
Brouwer, Elizabeth, 349
Bukhman, Gene, 191
Bulgaria, ischemic heart disease in, 138
Bull, Fiona, 79
burden of disease
asthma, 263–65
Chagas disease, 203
chronic obstructive pulmonary disease (COPD), 263–67
chronic respiratory diseases, 263–69, 266–67f
congenital heart disease (CHD), 191–92
diabetes, 209–12, 377
dyslipidemia, 390
heart failure, 173–77, 175–76f, 176f
hypertension, 389–90
ischemic heart disease (IHD), 136–40, 137m, 138–39f
obesity/overweight, 117–18
peripheral artery disease (PAD), 256
physical activity and inactivity, 80–81f, 80–82
rheumatic heart disease (RHD), 197
stroke, 157–59
Burney, Peter, 263
C
CABG (coronary artery bypass graft), 143, 185
calcium channel blockers, 163, 179, 333, 391–93
Callender, T., 181b
Cambodia
community-based care in, 320–21
diabetes in, 217
integrated care in, 294
kidney disease in, 239–40
Cameroon
community-based care in, 306, 308–10
quality of care in, 343
tobacco use in, 68
Canada
cost-effectiveness of interventions in, 358
ischemic heart disease in, 143–45
modifiable, 28–30
nonmodifiable, 27–28
obesity/overweight, 29
physical inactivity, 29–30
reducing, 32
social and ecological determinants, 30–32, 33

tobacco use, 28

cardiovascular disease (CVD). See also cardiovascular, respiratory, and related disorders (CVRDs); ischemic heart disease (IHD)
mortality rates, 4
tobacco use and, 57–78. See also tobacco use
CVD mortality rates and, 64
CVD outcomes and, 63–67, 64b, 64f
CVD pathophysiology and mechanisms, 58–62, 59–60f
CVD risk factors, 62–63
carotid and cerebrovascular diseases, 65
carotid endarterectomy, 165
carotid stenosis surgery, 166
catecholamines, 58–59, 61–62, 66
Cawley, J., 109
CCC (chronic Chagas cardiomyopathy), 202–4
CD. See Chagas disease
CDSS (clinical decision support system), 317–19, 343
Cecchini, M., 110
Centers for Disease Control and Prevention, 392
Chagas disease (CD), 191, 202–4
burden of disease, 203
heart failure and, 173, 176
interventions, 203
  cost-effectiveness, 203–4
  natural history, 202–3
  pathogenesis, 202–3
  risk factors, 27
Chan, Juliana, 209
Chandrasekar, Eeshwar, 209
CHD. See coronary heart disease
Chen, Jie, 157
children
  asthma and, 263–64
BMI
  in childhood and adolescence, 42–43
  in infancy, 42
  cardiometabolic disease and, 47–48
height in childhood, 43
mortality rates, 49, 110, 350, 353
obesity/overweight, 31–32, 44, 47, 125, 127–28, 354
weight gain and growth, 42–43, 47–48
Chile
  community-based care in, 314–15
  ischemic heart disease in, 142
China
  congenital heart disease in, 191, 194
  cost-effectiveness of interventions in, 353–54, 360, 369–70, 372–73
diabetes in, 210, 213, 217
diet and nutrition in, 106, 110
health care costs in, 8
integrated care in, 289–91, 293, 295
ischemic heart disease in, 137, 140–42
kidney disease in, 236, 240, 243, 245
obesity/overweight in, 118, 120–22, 124–27, 129–30
peripheral artery disease in, 8–9
physical activity in, 12, 82
quality of care in, 335
stroke in, 157, 159, 162–64, 166–67
cholesterol. See also dyslipidemia
cardiometabolic disease and, 46
community-based care and, 317
cost-effectiveness of interventions, 356–58
high-density lipoprotein (HDL), 29, 46, 61–62, 390, 396
interventions, 389–90, 397
natural history, 202–3
pharmacological interventions, 242
policy implications, 389–90, 397
prevalence, 389–90, 397
quality of care, 335
stroke in, 157, 159, 162–64, 166–67
cholesterol.
China
  congenital heart disease in, 191, 194
  cost-effectiveness of interventions in, 353–54, 360, 369–70, 372–73
diabetes in, 210, 213, 217
diet and nutrition in, 106, 110
health care costs in, 8
integrated care in, 289–91, 293, 295
ischemic heart disease in, 137, 140–42
kidney disease in, 236, 240, 243, 245
obesity/overweight in, 118, 120–22, 124–27, 129–30
peripheral artery disease in, 8–9
physical activity in, 12, 82
quality of care in, 335
stroke in, 157, 159, 162–64, 166–67
cholesterol. See also dyslipidemia
cardiometabolic disease and, 46
community-based care and, 317
cost-effectiveness of interventions, 356–58
high-density lipoprotein (HDL), 29, 46, 61–62, 390, 396
interventions, 389–90, 397
natural history, 202–3
pharmacological interventions, 242
policy implications, 389–90, 397
prevalence, 389–90, 397
quality of care, 335
stroke in, 157, 159, 162–64, 166–67
cholesterol.

China
  congenital heart disease in, 191, 194
  cost-effectiveness of interventions in, 353–54, 360, 369–70, 372–73
diabetes in, 210, 213, 217
diet and nutrition in, 106, 110
health care costs in, 8
integrated care in, 289–91, 293, 295
ischemic heart disease in, 137, 140–42
kidney disease in, 236, 240, 243, 245
obesity/overweight in, 118, 120–22, 124–27, 129–30
peripheral artery disease in, 8–9
physical activity in, 12, 82
quality of care in, 335
stroke in, 157, 159, 162–64, 166–67
cholesterol.
Index

mortality and morbidity trends, 27–28
pharmacological management, 274–75
prevention, 269
primary care centers and, 15
risk factors, 263–67
tobacco use and, 65
chronic respiratory diseases, 263–86, 264t.
See also specific conditions
asthma, 263–65
assessment, 271–72
barriers to care, 272–73
diagnosis, 271
pharmacological management, 272
bronchiectasis, 268–69, 276
burden of disease, 263–69, 266–67
chronic airway obstruction and COPD, 265–66
clinical course and management, 273–74
diagnosis, 273
pharmacological management, 274–75
chronic bronchitis, 268–69
community-based care and, 305–6, 310
idiopathic low FVC, 266–68, 275
interventions
cost-effectiveness, 359
management, 271–76
primary prevention, 269, 269b
principles of care, 270, 270b
mortality and morbidity rates, 23–25, 27–29
restrictive lung disease and fibrosis, 268
diagnosis, 275
treatment, 275–76
risk factors, 31, 33
systems and organization of care, 276–78, 277t, 278b
tobacco use and, 66
cigar and cigarette smoking. See tobacco use
Civil Servant Medical Benefit Scheme (CSMBS, Thailand), 383
CKD. See chronic kidney disease
claudication, 64, 253–54, 256–58
clinical decision support system (CDSS), 317–19, 343
clinical interventions
community-based care and, 306
cost-effectiveness, 10, 355, 372
diabetes, 218
obesity, 129
cognitive rehabilitation, 168
collaborative care, 294, 297, 312–13
Colombia
community-based physical activity programs in, 90b
physical activity in, 14, 87, 89, 92–93
priority-setting for treatments in, 378–82, 384
community-based health care, 305–26
case studies, 317–22, 318–20f
rheumatic heart disease (RHD), 199
self-management, 312–16, 313t, 316b, 317f
cost-effectiveness, 315–16
education in, 314–15
target populations, 314
technology for, 315
theories of, 313–14
stroke, 164
task-shifting, 305–12, 307–9, 311b
congenital heart disease (CHD), 191–96
burden of disease, 191–92
categories of, 191, 192t
curative care and treatment, 15, 194–95
hypertension and, 390
interventions, 192–94
cost-effectiveness, 195–96
neonatal screening, 194
prenatal screening, 193–94, 193t
prevention, 192–93
screening, 193–94, 195–96
palliative care and treatment, 194–95
prevalence rate, 191
risk factors, 26, 192
treatment, 194–95
access to, 10, 15
cost-effectiveness, 195–96
Congleton, T. M., 162
Consortium for the Epidemic of Nephropathy in Central America and Mexico, 241b
Consortium of Health-Orientated Research in Transitioning Societies, 42, 49
Control of Blood Pressure and Risk Attenuation (COBRA), 314
COPD. See chronic obstructive pulmonary disease
Cornelson, L., 362n2
coronary artery bypass graft (CABG), 143, 185
Coronary Artery Risk Development in Young Adults Study, 85
coronary heart disease (CHD). See also heart failure; ischemic heart disease
cardiometabolic disease and, 37, 40, 42–45, 48
community-based care, 312
cost-effectiveness of interventions, 354
diabetes and, 210–11, 214
diet and, 102–4
hypertension and, 389–90, 394–96
integrated care and, 288, 294
ischemic heart disease and, 137
physical activity and, 82–83, 83f, 86–87
quality of care and, 335, 341
risk factors, 29
stroke and, 160, 163
tobacco use and, 64–70
coronary vasoconstriction, 58b
corticosteroids, 272, 274–75
cost

cardiometabolic disease interventions, 49
Chagas disease (CD) interventions, 203–4
chronic respiratory disease interventions, 270, 272, 277
community-based care, 306, 308–9, 314–16
congenital heart disease interventions, 194–95
diabetes interventions, 211–12, 214–15, 218–19, 224
health care, generally, 57, 65–66, 86–87, 109, 124, 140
heart failure interventions, 178, 180–81, 183–84
hypertension interventions, 397
indirect, 87, 140, 159, 195, 212, 321, 390
ischemic heart disease, 140, 143
kidney disease interventions, 235, 238, 244–47
obesity/overweight interventions, 124, 125, 127–31
peripheral artery disease interventions, 258
physical activity interventions, 86–87, 89, 91–92
priority-setting for treatments and, 383–84
quality of care and, 343–44
rheumatic heart disease interventions, 201–2
stroke interventions, 166, 168
treatment, 9–17, 360–61
cost-effectiveness of interventions, 10–13, 11b
acute and hospital-based care, 359–60
Chagas disease, 203–4
cholesterol, 357
chronic kidney disease (CKD), 245–46
community-based care, 355–56
congenital heart disease (CHD), 195–96
diabetes, 217–19, 220t, 357
diet and nutrition, 109–11, 352–53
dyslipidemia, 397
extended cost-effectiveness analyses (ECEAs), 11, 16, 369–73
first-level hospital care, 357–59
heart failure, 183–84, 185t, 359
hypertension, 357, 370t, 371–72, 397
individual-level interventions, 355–60
acute and hospital-based care, 359–60
cholesterol, 357
community-based care, 355–56
diabetes, 357
first-level hospital care, 357–59
heart failure, 359
hypertension, 357, 370t, 371–72
ischemic heart disease, 359–60
kidney disease, 360
medication availability and adherence, 358–59
primary health center care, 356–57
respiratory conditions, 359
rheumatic heart disease, 357
screening, 355–56
ischemic heart disease, 145, 359–60
kidney disease, 238, 360
mass media policies, 353–55
medication availability and adherence, 358–59
obesity/overweight, 127–30, 128t, 130r
peripheral artery disease (PAD), 258–60
physical activity, 91–92, 354–55
population-level interventions, 350–55, 350f
diet and nutrition, 352–53
mass media policies, 353–55
physical activity, 354–55
regulatory policy, 353–55
salt consumption, 353–54, 370t, 371
tobacco use, 350–52, 351t, 370–71, 370r
tans fats consumption, 353–54
primary health center care, 356–57
ratios, 12, 92, 110, 130, 350, 352–53, 355
regulatory policy, 353–55
respiratory conditions, 359
rheumatic heart disease, 201–2, 357
salt consumption, 353–54, 370t, 371
screening, 355–56
self-management, 315–16
stroke, 165, 168
threshold for, 130, 355, 384
tobacco use, 350–52, 351t, 370–71, 370r
tans fats consumption, 353–54
counseling, dietary, 47, 86
Criqui, Michael H., 253
Critchley, J. A., 70
critical limb ischemia, 257–58
cyclophosphamide, 242
D
D’Alessandro, A., 66
DALYs (disability-adjusted life-years)
Chagas disease and, 203–4
congenital heart disease and, 191–92
cost-effectiveness of interventions and, 11–12, 350–54, 358–59
diabetes and, 211–12
diet and, 104, 110
heart failure and, 184–85
hypertension and, 390
ischemic heart disease and, 135, 137, 139–40, 145
obesity/overweight and, 127–30
physical activity and, 87
priority-setting for treatments and, 375, 377, 383
rheumatic heart disease and, 197
risk factors and, 4, 25, 27–29
stroke and, 157–58, 169
death rates. See mortality rates
dementia, 64–65, 82, 86
Danmark
   cardiometabolic disease in, 47
diabetes in, 215
diet and nutrition in, 108
integrated care in, 292–93
taxation of unhealthy foods and beverages in,
   362n1
depression
   community-based care and, 315
diabetes and, 210, 212, 214, 217, 288, 295, 297
integrated care and, 287–88
physical activity and, 83, 86–87
risk factors, 30
stroke and, 158–59, 161, 167
developmental origins of health and
disease (DOHaD) for cardiometabolic
disease, 39–40, 40f
adjustments, 45
confounding issues, 45
genetic effects, 45
interventions, 37, 39–40, 49
measurement errors, 45
diabetes, 209–34
burden of disease, 209–12, 377
cancer and, 210
cardiometabolic disease and, 39, 42
chronic kidney disease (CKD) and, 210
community-based care, 314
complications of, 6, 12, 210–11, 215, 219
coronary heart disease (CHD) and, 210
depression and, 217, 288, 295, 297
diagnosis, 215–16
diet and, 104
disability and, 211–12
end-stage renal disease (ESRD) and, 210, 241–42
heart failure and, 210
HIV/AIDS and, 292–94, 293r
hypertension and, 9, 240, 308–9, 320–21, 331–32,
   340, 343, 384, 392, 394, 396
integrated care and, 289–93
interventions, 9, 213–15, 217, 220
cost-effectiveness, 217–19, 220r, 356, 357
management, 144, 214–15, 216, 220, 308
prevention, 213–14, 216, 219
priorities, 221, 221–23r
screening, 213, 215, 219, 396
ischemic heart disease and, 136
knowledge gaps, 221, 223
management of, 144, 214–15, 216, 220, 308
maternal, 39, 48, 192
mental health and, 287–88
mortality and morbidity trends, 27, 211–12, 211r
obesity/overweight and, 122
physical activity and, 84–85, 84–85f
prevalence rate, 48, 63, 109, 209–10, 214, 216,
   288–90, 292, 381
prevention, 12, 213, 216–18, 221, 223
priority-setting for treatments, 375, 377
quality of care and, 327
risk factors, 24–26
stroke and, 159–60, 210
tobacco use and, 63
treatment, 216–17
tuberculosis and, 288–92, 289f, 290–91r
Diabetes Prevention Program (DPP), 84, 216, 222, 311
diabetic retinopathy, 215, 220–21
diagnosis
   chronic obstructive pulmonary disease (COPD), 273
diabetes, 215–16
   heart failure, 173
   peripheral artery disease (PAD), 253–54
   stroke, 162
dialysis, 15, 64, 210, 235–40, 242–43, 375
Diep, L., 83
diet and nutrition, 101–15
carbohydrates, 121–22
cardiometabolic disease and, 39, 43, 46
chronic respiratory diseases and, 264, 267, 271
community-based care, 314
counseling, 47, 86
fatty acids, 14, 102, 104, 143, 353–54
folate deficiency, 192
grains, 102–4, 122, 124–25, 131
interventions, 105–9, 105r
cost-effectiveness, 109–11, 352–53
fiscal policies, 107, 107f
local food environment, 108
mass media campaigns, 105–7
multicomponent interventions, 109
organizational settings, 107–8
pregnancy and, 46–47
taxation of unhealthy beverages and foods, 108–9
trans fats restrictions, 108
micronutrients, 46–47, 121–22
obesity/overweight and, 117–18, 121–24,
   127–28, 131
risk factors, 102–5, 103–4r
salt consumption, 16, 110, 163, 165, 353–54, 370r,
   371–73
stroke and, 160–61
sugar and sugar-sweetened beverages (SSBs), 11–13, 17, 102–9, 119, 123–28, 131, 222, 266, 352–53
trans fats consumption, 14, 102, 104, 106, 108, 353–54
vegetables, 13, 28, 32–33, 103–8, 124–26, 129, 131, 160–62, 169, 266
digital health strategies, 164–65
digoxin, 178–79, 186
Dirks, John, 235
disability
chronic respiratory diseases and, 276
community-based care and, 316–17
cost-effectiveness of interventions, 11, 16–17, 357
diabetes and, 211–12
heart failure and, 174, 184
integrated care and, 288
ischemic heart disease and, 135
primary care centers and, 3–4
quality of care and, 328
risk factors, 25–28
stroke and, 157–58, 160–61, 166–67
diuretics, 6, 15, 163, 177, 181, 183–84, 186, 359, 391–93, 395
DOHaD. See developmental origins of health and disease
Doll, R., 64
DPP. See Diabetes Prevention Program
drugs. See pharmacological interventions
Dugani, Sagar B., 135
dyslipidemia
burden of disease, 390
cost-effectiveness of interventions, 397
interventions, 393–95
polypills, 395
screening, 396
statins, 394. See also statins
tobacco use and, 62

E
East Asia and Pacific. See also specific countries
congenital heart disease in, 192
diabetes in, 220
heart failure in, 176, 185
ischemic heart disease in, 137–38, 141
kidney disease in, 245
peripheral artery disease in, 256
stroke in, 157
ECEAs (extended cost-effectiveness analyses), 11, 16, 369–73
echocardiography, 173, 178, 182, 184, 186, 194, 199, 201, 357, 396
Egypt, Arab Republic of
diabetes in, 210
priority-setting for treatments in, 378–79

tobacco use in, 68
e-Health, 164
ejection fraction, 177–78, 181–82
electronic nicotine delivery systems (electronic cigarettes), 69
El Nahas, Meguid, 235
El Salvador, kidney disease in, 241
EMLs. See essential medicines lists
endothelial dysfunction, 58–62, 58b
endovascular therapy, 257–58
end-stage renal disease (ESRD), 235, 239–42
diabetes and, 210, 215, 219–20, 241–42
dialysis, 242
epidemiology of, 240
hypertension and, 241–42
interventions, 241–42
cost-effectiveness, 357, 371
prevalence, 240
priority-setting for treatments, 383
transplantation, 243–44
treatment, 242–45
Engelgau, Michael, 327
ESRD. See end-stage renal disease
essential medicines lists (EMLs), 375, 377–78
estimated glomerular filtration rate (eGFR), 239
Ethiopia
cost-effectiveness of interventions in, 370–71
hypertensive treatment in, 16, 371–72
rheumatic heart disease in, 197
Europe and Central Asia. See also specific countries
diabetes in, 211, 220
heart failure in, 174, 176, 185
ischemic heart disease in, 138–39
kidney disease in, 245
peripheral artery disease in, 256–57, 259
European Medicines Agency, 377
exercise. See physical activity
extended cost-effectiveness analyses (ECEAs), 11, 16, 369–73

F
Fall, Caroline H. D., 37
fatty acids, 14, 102, 104, 143, 353–54
FCTC. See Framework Convention on Tobacco Control
Feigin, Valery, 157
Ferrante, D., 110
fibrinogen, 61–62, 67
fibrosis and restrictive lung disease, 268, 275–76
Figueira, F. R., 84
financial risk protection (FRP), 2, 9, 11, 16–17, 369–73
Finland
cardiometabolic disease in, 42–43, 45, 48
diabetes in, 213, 216
diet and nutrition in, 105, 109
kidney disease in, 238
physical activity in, 92–93
taxation of unhealthy foods and
beverages in, 362n1
Finnish Diabetes Prevention Trial, 84
fiscal policies, 13–14, 107, 350, 352
folic acid, 46–47, 166, 192
food advertising and labeling, 105, 123, 124–25,
129–31
Food and Drug Administration (U.S.), 274
Football Fans in Training program, 91
forced vital capacity (FVC), 265–68, 275
Forouhi, N. G., 290
Forsdahl, A., 37
Fowkes, F. Gerald R., 253
Framework Convention on Tobacco
Control (FCTC), 9, 32, 70, 144
Framingham Heart study, 23, 165
France
diet and nutrition in, 107–8
ischemic heart disease in, 137
obesity/overweight in, 125
priority-setting for treatments in, 382
taxation of unhealthy foods and
beverages in, 362n1
Freeman, S. D., 162
free trade agreements, 119
Freinkel, N., 40
Friends of Aldo Castenada Foundation, 196
Frisvold, D., 109
FRP. See financial risk protection
fuel-mediated teratogenesis, 40–41
FVC (forced vital capacity), 265–68, 275
G
The Gambia, nutrition during pregnancy in, 46
Garrett, S., 92
Gaziano, Thomas A., 1, 135, 349, 389
GDM. See gestational diabetes mellitus
gender issues
physical activity, 80, 91b
tobacco use, 65
generic medications, 8, 17, 145–46, 358
genetics
developmental origins of health and disease
(DOHaD), 45
obesity/overweight, 123
tobacco use and, 62
George, J., 238
gestational diabetes
  cardiometabolic disease and, 40–41, 41f, 47
  congenital heart disease and, 196
defined, 209
  screening for, 217, 396
GFR (glomerular filtration rate), 239, 243–44
Glassman, Amanda, 375
Global Advocacy for Physical Activity Initiative, 88
  See also burden of disease
Global Initiative for Asthma (GINA), 270–73
Global Initiative for Chronic Obstructive Lung Disease
(GOLD), 265
Global Physical Activity Questionnaire (GPAQ), 81
Global Registry of Acute Coronary Events, 142
Global Strategy on Diet, Physical Activity and Health
(UN), 92, 107
glomerular filtration rate (GFR), 239, 243–44
Goenka, Shifalika, 79
GOLD (Global Initiative for Chronic Obstructive Lung
Disease), 265
GPAQ (Global Physical Activity Questionnaire), 81
glasses, 102–4, 122, 124–25, 131
Green, R., 362n2
Guatemala
cardiometabolic disease in, 46
community-based care in, 310
cost-effectiveness of interventions in, 356
hypertension in, 397
Gulf Registry of Acute Coronary Events, 142, 143
Gupta, Rajeev, 389
H
Harikrishnan, S., 181b
Hasan, Babar, 191
Hawkesworth, S., 46
HCV (hepatitis C virus), 293
HDL. See high-density lipoprotein
health care costs. See also cost
diet and nutrition, 109
ischemic heart disease in, 140
obesity/overweight, 124
physical activity and, 86–87
tobacco use and, 57, 65–66
health care providers
  community-based care and, 305, 307, 313–14, 316
  integrated care and, 297
  ischemic heart disease and, 136, 145
  obesity/overweight and, 130–31
  physical activity and, 88
  quality of care and, 328, 334–35, 342
  rheumatic heart disease and, 200
  stroke and, 162, 164, 166–67
health technology assessment (HTA), 369, 375, 384, 386
heart disease. See congenital heart disease; coronary heart disease; ischemic heart disease
heart failure, 173–90
burden of disease, 173–77, 175–76f, 176f
causes, 173
diabetes and, 210
diagnosis, 173
health service arrangements, 180–82
interventions, 177–80, 183
angiotensin-converting enzyme (ACE) inhibitors, 178, 184
angiotensin receptor blockers, 178
anticoagulants, 179
beta blockers, 177–78, 184
case management, 180
cost-effectiveness, 183–84, 185t, 359
devices, 180, 184
digoxin, 178–79
diuretics, 177, 183–84
exercise-based rehabilitation, 179–80
inotropes, 179
mineralocorticoid receptor antagonists, 178, 184
noninvasive positive pressure ventilation, 179
pharmacological, 177–79
mortality rates, 174, 175t
prevalence rates, 174, 176t
stages and classes of, 174b
tobacco use and, 58, 62, 64–65, 68, 70
hemodialysis, 15, 239, 245–46, 383–84
hemorrhagic stroke, 15, 30, 65, 83, 159–61, 165, 169
Henry Ford Exercise Testing Project, 85
hepatitis C virus (HCV), 293
Hersch, Fred, 305
HHE (home health education), 315, 343
high blood pressure. See hypertension
high-density lipoprotein (HDL), 29, 46, 61–62, 390, 396
high-income countries (HICs)
cardiometabolic disease in, 39, 41–42, 44
cardiovascular, respiratory, and related disorders (CVRDs) in, 24–26, 30
Chagas disease in, 203–4
Chagas disease in, 203–4
chronic respiratory diseases in, 269–71
community-based care in, 311
congenital heart disease in, 191–95
diabetes in, 213–15, 217–20
heart failure in, 173–74, 183–84
hypertension in, 389–90
integrated care in, 292
ischemic heart disease in, 135–37, 143–45
obesity/overweight in, 117, 119–21
peripheral artery disease in, 253–58
physical activity in, 80, 86–89
quality of care in, 341–42, 344–45
stroke in, 157, 162–63, 168–69
HTAP (Health Intervention and Technology Assessment Program), 384
HIV/AIDS
chronic respiratory diseases and, 269, 278
community-based care, 306
diabetes and, 217, 223, 292–94, 293t
integrated care and, 287, 290, 292–94
ischemic heart disease (IHD) and, 135–36
kidney disease and, 236, 240
priority-setting for treatments, 384
quality of care and, 331
home health education (HHE), 315, 343
homocysteine-lowering therapy, 166
Howard, K., 245
HTA (health technology assessment), 369, 375, 384, 386
Hu, Frank B., 117
Huffman, Mark D., 173, 203
Hungary
diet and nutrition in, 108
taxation of unhealthy foods and beverages in, 362n1
hypercholesterolemia, 390. See also dyslipidemia
hypersensitivity pneumonitis, 264, 268, 275–76
hypertension, 389–404
burden of disease, 389–90
diabetes and, 9, 240, 308–9, 320–21, 331–32, 340, 343, 384, 394
end-stage renal disease (ESRD) and, 241–42
interventions, 9, 390–93, 392–93t, 393f, 398b
antiplatelet therapy, 393
combination therapy, 393
cost-effectiveness, 357, 370t, 371–72, 397
pharmacological, 391
screening, 395–96
tobacco use and, 62–63
treatment, 330, 370, 372
I
ICDs. See implantable cardioverter defibrillators
ICERs. See incremental cost-effectiveness ratios
IDF. See International Diabetes Federation
idiopathic low FVC, 266–68, 275
idiopathic pulmonary fibrosis (IPF), 268, 275–76
IHDI. See ischemic heart disease
IMAI (Integrated Management of Adolescent and Adult Health), 277
impaired glucose tolerance (IGT), 37, 41, 84–85, 109, 210, 214, 315
implantable cardioverter defibrillators (ICDs), 15, 141, 147, 180, 183–84, 359
incremental cost-effectiveness ratios (ICERs)
Chagas disease, 204
community-based care, 315–16, 356
congenital heart disease, 195
diabetes, 217, 219–20
heart failure, 179, 184–85, 359
ischemic heart disease (IHD), 141, 143, 145, 147, 360
kidney disease, 245
rheumatic heart disease, 201–2
India
  cardiometabolic disease in, 39, 41–42
  community-based care in, 308–10, 317
  congenital heart disease in, 194, 196
cost-effectiveness of interventions in, 11–12, 351–53
diabetes in, 213, 216–18
  health care costs in, 8
  heart failure in, 181, 181b
hypertension in, 389
integrated care in, 289–90
  kidney disease in, 244
  obesity/overweight in, 121, 124, 126–27, 129–30
  physical activity in, 80, 82
  priority-setting for treatments in, 382
  quality of care in, 329, 334–35
  rheumatic heart disease in, 200–202
  stroke in, 167–68
  tobacco use in, 57
Indonesia
  integrated care in, 291
  priority-setting for treatments in, 378–80, 382
infectious diseases. See also specific diseases
chronic respiratory diseases and, 269
  community-based care, 306
  congenital heart disease and, 196
cost-effectiveness of interventions, 373
diabetes and, 210, 212, 223
integrated care and, 288–89
  kidney disease and, 237, 240
inflammation of vascular tissue, 58b, 61–62
Inglis, S. C., 180
inhaled corticosteroids, 7, 9, 12, 15, 271–72, 274, 359
in-hospital mortality
  heart failure, 179–81
  ischemic heart disease, 143
  kidney disease, 235–36
  quality of care and, 329
inotropes, 179
insulin
cardiometabolic disease and, 39, 43, 46–47
cost-effectiveness of, 12
diabetes treatment, 212, 214, 218, 222
integrated care and, 292
obesity/overweight and, 122
priority-setting processes and, 375, 377–79
  tobacco use and, 61, 63
insulin resistance
cardiometabolic disease and, 39, 41, 43, 45–46
  obesity/overweight and, 118
  physical activity and, 86
  tobacco use and, 59–61, 63
integrated care, 287–97, 294–95t, 295f, 298t
  adherence to treatment and, 296–97
  blood pressure (BP) and, 295, 297
  body mass index (BMI) and, 292
  cardiometabolic disease and, 296
  cholesterol and, 297
  chronic kidney disease (CKD) and, 288, 294
  chronic respiratory diseases, 277–78
  coronary heart disease (CHD) and, 288, 294
  depression and, 287–88
  diabetes and, 289–93
  disability and, 288
  health care providers and, 297
  HIV/AIDS and, 287, 290, 292–94
  infectious diseases and, 288–89
  insulin and, 292
  kidney disease and, 294
  obesity/overweight and, 292
  physical activity and, 288
  primary care centers and, 295, 297
  relative risk (RR) and, 292–93
  risk factors and, 287–88, 292
  self-management interventions, 295
  tuberculosis and, 287–92, 294
Integrated Management of Adolescent and Adult Health (IMAI), 277
INTERHEART study, 28, 65, 67, 68
intermittent claudication, 256–57
International Agency for Research on Cancer, 144
International Charter on Cardiovascular Prevention and Rehabilitation, 147
International Diabetes Federation (IDF), 27, 209–12, 214–15, 288, 290, 320, 378
International Physical Activity Questionnaire, 81
International Society of Nephrology, 237b
International Society of Peritoneal Dialysis, 239
International Study of Asthma and Allergies in Childhood, 264
International Union Against Tuberculosis and Lung Disease, 289
INTERSTROKE study, 28, 65, 159

interventions
cardiometabolic disease, 46–48
Chagas disease, 203
chronic kidney disease (CKD), 241, 243–44
cost-effectiveness, 243–46
renal replacement therapy, 245–46, 245f
screening, 245, 246b
chronic respiratory diseases
management, 271–76
primary prevention, 269, 269b
principles of care, 270, 270b
congenital heart disease (CHD), 192–94
cost-effectiveness, 195–96
neonatal screening, 194
prenatal screening, 193–94, 193t
prevention, 192–93
screening, 193–94, 195–96
diabetes, 9, 213–15, 217, 220
cost-effectiveness, 217–19, 220r, 357
management, 214–15
prevention, 213–14, 216, 219
priorities, 221, 221–23r
screening, 213, 215, 219, 396
diet and nutrition, 105–9, 105r
cost-effectiveness, 109–11, 352–53
fiscal policies, 107, 107r
local food environment, 108
mass media campaigns, 105–7
multicomponent interventions, 109
organizational settings, 107–8
taxation of unhealthy beverages and foods, 108–9
trans fats restrictions, 108
dyslipidemia, 393–95
cost-effectiveness, 397
polypills, 395
screening, 396
statins, 394
end-stage renal disease (ESRD), 241–42
essential package, 6–7r, 15–16
heart failure, 177–80, 183r
angiotensin-converting enzyme (ACE) inhibitors, 178, 184
angiotensin receptor blockers, 178
anticoagulants, 179
beta blockers, 177–78, 184
case management, 180
cost-effectiveness, 183–84, 185r, 359
devices, 180, 184
digoxin, 178–79
diuretics, 177, 183–84
exercise-based rehabilitation, 179–80
inotropes, 179
mineralocorticoid receptor antagonists, 178, 184
noninvasive positive pressure ventilation, 179
pharmacological, 177–79
hypertension, 9, 390–93, 392–93t, 393f, 398b
antiplatelet therapy, 393
combination therapy, 393
cost-effectiveness, 357, 370r, 371–72, 397
pharmacological, 391
screening, 395–96
ischemic heart disease (IHD), 140–47, 141–42r
access to medications, 145–46
acute management, 140, 142–43, 147
cardiac rehabilitation, 147
cardiogenic resynchronization therapy, 147
cost-effectiveness, 145, 359–60
implantable cardioverter defibrillators, 147
individual-level, 144–45
population-level, 144
secondary prevention, 143–46
kidney disease, 237
cost-effectiveness, 238, 360
mental health, 296–97
obesity/overweight, 123–27, 131r
agricultural policies, 124
bariatric surgery, 127
cost-effectiveness, 127–30, 128r, 130r
food advertising, 125
food labeling, 124–25
mass media campaigns, 125
nutritional policies, 124
pharmacological strategies, 126–27
prevention, 117, 122–24, 130–31
school-based interventions, 125–26
urban planning and design, 126
weight-loss diets, 126
workplace interventions, 125–26
patient-provider-level interventions, 332–43, 333r, 334f, 335b, 336–40r, 341f, 342b
acute phase, 332–34
chronic phase, 334–43
mobile communication technology and, 341, 342b
task-shifting, 341, 343
peripheral artery disease (PAD), 256–58
cost-effectiveness, 258–60
critical limb ischemia, 257–58
intermittent claudication, 256–57
physical activity, 87–91
community-based programs, 90b, 91
cost-effectiveness, 91–92, 354–55
primary health care, 88–89
public education campaigns, 89
sports systems and programs, 89, 91
transport and urban design, 89
whole-of-school programs, 88
prevention, 13–14
restrictive lung disease and fibrosis, 275–76
rheumatic heart disease (RHD), 197–201, 198
  cardiac surgery, 198–99
  community-based programs, 199
  cost-effectiveness, 201–2, 357
  echocardiography, 199
  primary prevention, 197
  primordial prevention, 199
  public policy, 200, 200r
  secondary prevention, 198, 201
  surgical care platforms, 199–200
  system-level interventions, 328–31, 329–30r, 331–32b
  acute phase, 328–29
  chronic phase, 329–31
IPF. See idiopathic pulmonary fibrosis
Iran
  kidney disease in, 244
  obesity/overweight in, 125
  quality of care in, 337, 339
  stroke in, 161, 168
  tobacco use in, 68
Irlam, J., 201
ischemic heart disease (IHD), 135–56
  burden of disease, 136–40, 137m, 138–39f
  cardiometabolic disease and, 38
  heart failure and, 173–77, 179, 181, 184–85
  HIV/AIDS and, 136
  hypertension and, 389–90, 395, 397
  interventions, 140–47, 141–42t
  access to medications, 145–46
  acute management, 140, 142–43, 147
  cardiac rehabilitation, 147
  cardiac resynchronization therapy, 147
  implantable cardioverter defibrillators, 147
  individual-level, 144–45
  population-level, 144
  secondary prevention, 143–46
  manifestations of, 136
  medications
    access to, 145–46
    adherence, 146–47
    mortality and morbidity trends, 26, 27f
    risk factors, 136
    tobacco use and, 67–68, 144
  ischemic stroke, 159–62
  community-based care, 316
  hypertension and, 390, 396
  mortality and morbidity rates, 27
  primary care centers and, 15
  risk factors, 30
  tobacco use and, 65
  treatment, 165–66
J
Jabour, Samer, 57
Janssen, I., 87
Japan
  Chagas disease in, 203
  diabetes in, 213
  diet and nutrition in, 106
  ischemic heart disease in, 137
  obesity/overweight in, 126
  stroke in, 165
  tobacco use in, 67
Jarvis, Deborah, 263
Jeemon, Panniyammakal, 327, 389
Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure, 163
Joseph, K. S., 48
Joshi, Rohina, 305
K
Kamano, Jemima H., 327
Katzmarzyk, P. T., 87
Kengne, Andre Pascal, 305
Khatibzadeh, S., 177
kidney disease, 235–52. See also chronic kidney disease (CKD); end-stage renal disease (ESRD)
  etiology, 236–37
  hypertension and, 393
  integrated care and, 294
  interventions, 237
  cost-effectiveness, 238, 360
  mortality and morbidity rates, 24–26, 236, 236t
  policy implications, 238–39, 238–39t
  prevalence, 235–36
  priority-setting for treatments, 383–86, 383b, 385b
  tobacco use and, 63–64
Kidney Help Trust of Chennai, 246b
Korea, Republic of
  diet and nutrition in, 106
  ischemic heart disease in, 137
  obesity/overweight in, 125
  priority-setting for treatments in, 384
Kramer, M., 48
Kudesia, Preeti, 327
Kumar, R. Krishna, 191
Kumaran, Kalyanaraman, 37
Kwan, G. F., 183
Kyrgyz Republic
diabetes in, 212
priority-setting for treatments in, 380

L
LABAs (long-acting beta2-agonists), 272, 274
Laine, J., 92
La Isla Foundation, 241b
Lambert, Vicki, 79
Latin America and Caribbean.
See also specific countries
Chagas disease in, 203–4
cost-effectiveness of interventions in, 353, 358
diabetes in, 211–12, 216, 220
diet and nutrition in, 110
heart failure in, 176, 185
ischemic heart disease in, 138–40, 142–43
kidney disease in, 236, 244–45
peripheral artery disease in, 257, 259–60
physical activity in, 88
priority-setting for treatments in, 376
rheumatic heart disease in, 200
stroke in, 157
LDL. See low-density lipoprotein
Lee, Edward S., 327
leukotriene receptor antagonists, 272
Levin, Carol, 349
Levy, D., 67
Li, Chaoyun, 157
LICs. See low-income countries
Lifestyle in Pregnancy and Offspring study, 47
life years (LYs)
cost-effectiveness of interventions and, 11, 350, 352, 354
diabetes and, 211
diet and, 103–4
hypertension and, 390
ischemic heart disease and, 135, 137
obesity/overweight and, 127
physical activity and, 87
priority-setting for treatments and, 375
stroke and, 157
lipids. See also cholesterol; dyslipidemia
diabetes and, 214
hypertension and, 394–96
interventions, 166
oxidation and tobacco use, 61
stroke and, 164
LMICs. See low- and middle-income countries
London Stroke Carers Training Course (LSCTC), 167
long-acting beta-agonists (LABAs), 272, 274
Look AHEAD study, 218
low- and middle-income countries (LMICs)
cardiometabolic disease in, 39, 41–44
cardiovascular, respiratory, and related disorders
(CVRDs) in, 23–30, 32–33
Chagas disease in, 202–4
chronic respiratory diseases in, 263–64, 271–72, 276–77
community-based care in, 305–6, 310–17
congenital heart disease in, 191–96
cost-effectiveness of interventions in, 12–14, 349–51, 353
diet and nutrition in, 108, 110
heart failure in, 179–81, 181b, 183–84
integrated care in, 288–90, 294–97
ischemic heart disease in, 135–37
obesity/overweight in, 118–22, 124–27
peripheral artery disease in, 253–54, 256, 258, 260
physical activity in, 87–89
primary care centers in, 16–17
priority-setting for treatments in, 375–78
quality of care in, 341–43
rheumatic heart disease in, 197–202
stroke in, 157–59, 161–69
low birth weight
cardiometabolic disease in, 37, 39, 43–45
chronic respiratory diseases and, 267–68
kidney disease and, 241
as risk factor, 30–31
low-density lipoprotein (LDL)
ischemic heart disease and, 146
management of, 389–91, 394, 396
physical activity and, 85
quality of care and, 335–36, 340
as risk factor, 28
stroke and, 163
tobacco use and, 61–62
low-income countries (LICs)
cardiometabolic disease in, 37, 39, 43–45
chronic respiratory diseases and, 267–68
kidney disease and, 241
as risk factor, 30–31

Lubinga, S. J., 202
Luo, Rong, 157
LYs. See life years

M
Magee, Matthew, 287
Malawi
chronic respiratory diseases in, 278
integrated care in, 294
Malaysia
ischemic heart disease in, 143
priority-setting for treatments in, 384
quality of care in, 342
Malik, Vasanti S., 117
Marin-Neto, J. Antonio, 191
Marks, Guy, 263
mass media campaigns
  cost-effectiveness of interventions and, 350–53, 360
diet and nutrition, 105–7
ischemic heart disease, 144
obesity/overweight, 124–25, 129–31
physical activity, 89
stroke, 162
Maternal and Infant Nutrition Interventions in Matlab (MINIMat), 46, 47
maternal obesity, 40–41, 41f, 47
maternal tobacco use, 44
Mauritius
diabetes in, 210
diet and nutrition in, 106, 109
ischemic heart disease in, 144
Mayosi, Bongani, 191
Mbanya, Jean-Claude, 1, 209
McGuire, Helen, 305
medication. See adherence to treatment; pharmacological interventions
mental health
diabetes and, 287–88
interventions, 296–97
metformin, 218
Mexico
chronic respiratory diseases in, 278
community-based care in, 310, 315
cost-effectiveness of interventions in, 10–12, 351, 353, 356
diabetes in, 218
diet and nutrition in, 108, 110
hypertension in, 397
integrated care in, 291
kidney disease in, 241–43, 245–46
obesity/overweight in, 119–20, 124–25, 127, 130
priority-setting for treatments in, 378–80
quality of care in, 330, 337, 342
stroke in, 163
taxation of unhealthy foods and beverages in, 12, 362n1
tobacco use in, 68
Micha, Renata, 101
micronutrients, 46–47, 121–22
MICs. See low- and middle-income countries; middle-income countries
Middle East and North Africa. See also specific countries
congenital heart disease in, 192
cost-effectiveness of interventions in, 358
diabetes in, 210–11, 220
heart failure in, 185
ischemic heart disease in, 138–39, 142–43, 146
kidney disease in, 244–45
peripheral artery disease in, 257, 259–60
physical activity in, 81, 92
middle-income countries (MICs). See also low- and middle-income countries
cardiovascular, respiratory, and related disorders (CVRDs) in, 23–29
chronic respiratory diseases in, 263–64
congenital heart disease in, 196, 198
cost-effectiveness of interventions in, 9–13, 352–53, 371
diet and nutrition in, 108, 110
heart failure in, 181
ischemic heart disease in, 139, 141–43
kidney disease in, 236
peripheral artery disease in, 255–56
physical activity in, 80
primary care centers in, 15, 16
priority-setting for treatments in, 377
quality of care in, 334–35, 345
stroke in, 168–69
mineralocorticoid receptor antagonists, 178, 184
Miranda, J. Jaime, 157
mitral regurgitation, 147
mobile communication technology, 341, 342b
Model List of Essential Medicines (WHO), 9, 14, 145, 147, 177
Montoya, Pablo Aschner, 209
MoPoTsyo Model of Care (Cambodia), 320–22
Moran, Andrew E., 67, 135, 327
morbidity rates
asthma, 27
cardiovascular, respiratory, and related disorders (CVRDs), 24–25, 24r, 25–26f, 26t
chronic obstructive pulmonary disease (COPD), 27
chronic respiratory diseases, 23–25, 27–29
diabetes, 27, 211–12, 211r
ischemic heart disease (IHD), 26, 27f
ischemic stroke, 27
kidney disease, 24–26
peripheral artery disease (PAD), 26–27, 256, 257–58f, 259–60f
stroke, 26, 27f, 157, 158m, 160, 162, 211, 389
Morocco, priority-setting for treatments in, 378–81
mortality rates, 4–8, 8f
asthma, 27

National Health Security Office (NHSO, Thailand), 383–84
National Institutes of Health (NIH), 162
National Kidney Foundation, 241
NEMLS. See national essential medicines lists
Nepal, cardiometabolic disease in, 46
nephropathy, 27
neuropathy, 27, 219
Neutral Protamine Hagedorn (NPH) insulin, 377, 379
New York Heart Association, 174b
New Zealand
diet and nutrition in, 106–7
obesity/overweight in, 126
physical activity in, 87–88
stroke in, 164
Ng, S. W., 82
Nigeria
diabetes in, 218
kidney disease in, 240, 242
quality of care in, 343
stroke in, 161
Nikolic, Irina, 349
noninvasive positive pressure ventilation, 179
North American Free Trade Agreement (NAFTA), 119
Norway
diet and nutrition in, 108
taxation of unhealthy foods and beverages in, 362n1
NRT (nicotine replacement therapy), 144–45, 271, 351
Nugent, Rachel, 1, 349, 369
nutrition. See diet and nutrition

O
obesity/overweight, 117–34
behavioral change and, 121
burden of, 117–18
cardiometabolic disease and, 40–41, 41f, 43–44, 47, 48
cardiovascular, respiratory, and related disorders (CVRDs) and, 29–31
children, 127–28
chronic respiratory diseases and, 264
community-based care, 312
congenital heart disease and, 193–94
diabetes and, 209, 213–14
diet and, 102, 109, 121–23
genetic factors, 123
income status and, 119–20
integrated care and, 292

N
NAFTA (North American Free Trade Agreement), 119
Naicker, Saraladevi, 235
Naidoo, Nadraj G., 253
Narayan, K. M. Venkat, 209, 287
National Autonomous University of Nicaragua at Léon, 241b
national essential medicines lists (NEMLS), 375, 377–79, 381–83, 386
National Health and Nutrition Examination Survey, 67
interventions, 123–27, 131r
agricultural policies, 124
bariatric surgery, 127
cost-effectiveness, 12–13, 127–30, 128r, 130r, 350, 352–54
food advertising, 125
food labeling, 124–25
mass media campaigns, 125
nutritional policies, 124
pharmacological strategies, 126–27
prevention, 117, 122–24, 130–31
school-based interventions, 125–26
urban planning and design, 126
weight-loss diets, 126
workplace interventions, 125–26

ischemic heart disease and, 136, 144

maternal, 40–41

physical activity and, 79, 83, 85–86, 120–21
prevalence, 41, 118–19, 122–23, 315, 353
risk factors, 118–23, 119f

sociocultural norms and, 121

socioeconomic status and, 119–20

stroke and, 160–61, 169

trade liberalization and, 119

urbanization and, 120


occupational therapy, 168

Oceania
hypertension in, 390
ischemic heart disease in, 137
peripheral artery disease in, 256, 260

O’Donnell, Martin, 157
Olasky, S. J., 67
Onen, Churchill, 389
Organisation for Economic Co-operation and Development (OECD), 13, 127, 129–30, 130r
organ transplantation, 243–44
Ortegon, M., 110
Osmond, Clive, 37
oxidative stress, 58b

P

PAD. See peripheral artery disease

Pakistan
community-based care in, 314–15
cost-effectiveness of interventions in, 12
diet and nutrition in, 106
integrated care in, 290
ischemic heart disease in, 140
kidney disease in, 244
priority-setting for treatments in, 378–80
palliative care and treatment, 194–95
passive smoking, 28
Patel, Anushka, 86, 305

PATH (Program for Appropriate Technology in Health), 320

patient-provider-level interventions
acute phase, 332–34
chronic phase, 334–43
mobile communication technology and, 341, 342b
quality of care, 332–43, 333r, 334f, 335b, 336–40r, 341f, 342b
task-shifting, 341, 343

PD. See peritoneal dialysis

Pedersen, J., 40

percutaneous coronary interventions (PCI), 12, 141, 143, 147, 360

Perez-Padilla, Rogelio, 263

peripheral artery disease (PAD), 253–62
burden of disease, 256
causes, 253–54
diagnosis, 253–54
epidemiology, 254
hypertension and, 390
interventions, 256–58
cost-effectiveness, 258–60
critical limb ischemia, 257–58
intermittent claudication, 256–57
ischemic heart disease and, 136
mortality and morbidity trends, 24, 26–27, 256, 257–58f, 259–60f
prevalence, 254, 255–56f
risk factors, 253, 254, 256, 260
tobacco use and, 64, 66

peritoneal dialysis (PD), 15, 236–39, 237b, 242, 383–86

Peru
obesity/overweight in, 125
priority-setting for treatments in, 378–80

pharmacological interventions
chronic kidney disease (CKD), 242
chronic obstructive pulmonary disease (COPD), 274–75
generic medications, 8, 17, 145–46, 358
heart failure, 177–79
hypertension, 391
ischemic heart disease, 145–47
obesity/overweight, 126–27
stroke, 163

Philippines
cost-effectiveness of interventions in, 12
priority-setting for treatments in, 378–80, 382
physical activity, 79–100
cardiometabolic disease and, 40, 47, 82–86
cardiovascular, respiratory, and related disorders (CVRDs) and, 28, 30–31
community-based care and, 312, 314
coronary heart disease and, 82–83, 83f
defined, 80b
diabetes and, 84–85, 84–85f, 222–23
diet and, 104–5
economic costs of inactivity, 86–87
exercise-based rehabilitation, 179–80
gender issues, 91b
hypertension and, 389
integrated care and, 288
interventions, 14, 87–91
community-based programs, 90b, 91
cost-effectiveness, 12, 91–92, 350, 354–55
primary health care, 88–89
public education campaigns, 89
sports systems and programs, 89, 91
transport and urban design, 89
whole-of-school programs, 88
ischemic heart disease and, 136
obesity/overweight and, 119–23, 125–28
policy implications, 92–93
prevalence and burden of inactivity, 80–81f, 80–82
sedentary activity and sitting, 86
stroke and, 83–84, 160–62, 165, 169
physical therapy, 168
phytoestrogens, 44
pipe smoking, 68
polychlorinated biphenyls, 44
polypills, 146, 163–64, 395
Popkin, B. M., 82
population-level interventions
cost-effectiveness, 13, 349–51, 355, 361, 372
diabetes, 223
diet and nutrition, 101, 109–10
ischemic heart disease, 140, 144
obesity/overweight, 123, 131
Poulter, Neil, 389
Prabhakaran, Dorairaj, 1, 23, 57, 101, 173, 287, 389
Practical Approach to Lung Health in South Africa (PALSA), 278b
Pratt, Michael, 79, 87
prediabetes, 12, 210, 213–14, 216–17, 342, 396
pregnancy. See also gestational diabetes
cardiometabolic disease and, 37, 39, 41, 44, 46–49
cardiovascular, respiratory, and related disorders (CVRDs) and, 30, 31
Chagas disease and, 203
chronic respiratory diseases and, 267, 269
genital heart disease and, 192–93
obesity/overweight and, 40–41, 41f, 47, 118
prenatal screening, 193–94, 193f
rheumatic heart disease and, 197
tobacco use and, 44
prevalence
chronic kidney disease (CKD), 240
genital heart disease (CHD), 191
diabetes, 48, 63, 109, 209–10, 214, 216, 288–90, 292, 381
end-stage renal disease (ESRD), 240
heart failure, 174, 176t
kidney disease, 235–36
obesity/overweight, 41, 118–19, 122–23, 315, 353
peripheral artery disease (PAD), 254, 255–56f
physical activity and inactivity, 80–81f, 80–82
prevention
asthma, 269
chronic obstructive pulmonary disease (COPD), 269
genital heart disease (CHD), 192–93
cost-effectiveness, 13–14
diabetes, 12, 213–14, 216–19, 221, 223
heart failure, 179
ischemic heart disease (IHD), 143–46
obesity/overweight, 117, 122–24, 130–31
rheumatic heart disease (RHD), 197, 198, 199, 201
statins as, 394–95
stroke, 161–65, 179, 357
antiplatelet therapy, 166
atrial fibrillation control, 164
blood pressure control, 166
carotid stenosis surgery, 166
cost-effectiveness, 165
digital health strategies, 164–65
family support, 166–67
high blood pressure, 163
homocysteine-lowering therapy, 166
lipid-lowering therapy, 166
pharmaceutical treatments, 163
polypill use, 163–64
primary, 162–65
secondary, 166–67
self-management, 166–67
sodium reduction, 163
tobacco use reduction, 162
primary care centers, 12, 14–16. See also quality of care
chronic obstructive pulmonary disease (COPD) and, 15, 273–74
chronic respiratory diseases and, 270, 276–78, 277t, 278b
community-based care and, 305, 310
cost-effectiveness, 356–57
heart failure, 180–82
hypertension and, 397
improvement of, 3b
integrated care and, 295, 297
kidney disease and, 242, 244
obesity/overweight and, 129
physical activity and, 88–89
role of, 14–16
priority-setting for treatments, 375–88
diabetes, 377–83, 379

tobacco use and, 63, 65–68, 70
Remuzzi, Giuseppe, 235
renal replacement therapy (RRT), 237–38, 240,
245–47, 245f, 383
respiratory diseases, chronic, 140, 263, 269–70,
274, 276, 375
restrictive lung disease and fibrosis, 268, 275–76
retinopathy, 27, 215
RF. See rheumatic fever
RHD. See rheumatic heart disease
rheumatic fever (RF), 6, 197–98, 200, 357
rheumatic heart disease (RHD), 197–202
burden of disease, 197
cardiovascular, respiratory, and related disorders
(CVRDs) and, 27
heart failure nad, 176–77
hypertension and, 390
interventions, 197–201, 198t
cardiac surgery, 198–99
community-based programs, 199
cost-effectiveness, 13, 201–2, 357
echocardiography, 199
primary prevention, 197
primordial prevention, 199
public policy, 200, 200t
secondary prevention, 198, 201
surgical care platforms, 199–200
mortality rates, 197
natural history, 197
pathogenesis, 197
risk factors, 197
Riella, Miguel, 235
risk factors, 9–10
alcohol use, 30
asthma, 263–65
cardiometabolic disease, 37–39, 38f, 41
cardiometabolic disease, 37–39, 38f, 41
cardiometabolic disease, 37–39, 38f, 41
cardiometabolic disease, 37–39, 38f, 41
cardiometabolic disease, 37–39, 38f, 41
cardiometabolic disease, 37–39, 38f, 41
cardiometabolic disease, 37–39, 38f, 41
Chagas disease, 27
chronic obstructive pulmonary disease (COPD),
263–67
chronic respiratory diseases, 31, 33,
263–68
congenital heart disease, 26, 192–93, 196
coronary heart disease, 29
cost-effectiveness of interventions and, 355–58, 360–61
depression, 30
diet and nutrition, 14, 102–5, 103–4t, 122, 161
disability, 25–28
dyslipidemia, 28
eye childhood determinants, 30–31
heart failure, 174
high blood pressure, 29, 159
hypertension, 390–91, 397
integrated care and, 287–88, 292
ischemic heart disease, 136, 140
ischemic stroke, 30
kidney disease, 240–41
middle childhood determinants, 31–32
modifiable, 23, 28–30, 159–61, 192, 196
nonmodifiable, 27–28, 395
obesity/overweight, 29, 118–23, 119f, 129, 161
peripheral artery disease (PAD), 253, 254, 256, 260
physical inactivity, 29–30, 86, 161
rheumatic heart disease (RHD), 197
social and ecological determinants, 30–32, 33
stroke, 28–29, 65, 70, 83, 157, 159–61, 159–60t, 163–64, 166, 169
tobacco use, 28, 63, 65–66, 70, 160
rituximab, 242
Rivero-Ayerza, M., 180
Roth, Greg A., 173
Rotterdam Study, 66
Roux, L., 91
Roy, Ambuj, 57
RR. See relative risk
RRT. See renal replacement therapy
Rubinstein, Adolfo, 101
Russian Federation
ischemic heart disease in, 138
obesity/overweight in, 127, 130
stroke in, 161
tobacco use in, 68
Rwanda
heart failure in, 183, 184t
integrated care in, 294
S
Sakuma, Yuna, 375
salt consumption, 16, 110, 163, 165, 353–54, 370r, 371–73
Sampson, Uchechukwu K. A., 253
screening
chronic kidney disease (CKD), 245, 246b
congenital heart disease (CHD), 193–94, 195–96
neonatal screening, 194
SMBG. See Self-Monitoring of Blood Glucose
smokeless tobacco, 68–69
smoking. See tobacco use
sodium. See salt consumption
Soudarssanane, M. B., 201
South Africa
chronic respiratory diseases in, 278b
community-based care in, 306–8, 310
Srivastava, Deepa, 181
stroke, 166–67
target populations, 314
technology for, 315
theories of, 313–14
self-monitoring of blood glucose (SMBG), 12, 214, 217–18, 220
short message service (SMS), 315, 337, 340, 342
Siegel, Karen R., 209
Singapore, diet and nutrition in, 105–6
Sliwa, Karen, 173
Small, C. W., 162
SMBG. See Self-Monitoring of Blood Glucose
smokeless tobacco, 68–69
smoking. See tobacco use
sodium. See salt consumption
Soudarssanane, M. B., 201
South Africa
chronic respiratory diseases in, 278b
community-based care in, 306–8, 310
cost-effectiveness of interventions in, 12, 353, 356–58
diabetes in, 213
diet and nutrition in, 107, 110
hypertension in, 397
integrated care in, 290, 292–93
ischemic heart disease in, 136, 140, 142, 144–46
kidney disease in, 242, 244
obesity/overweight in, 120, 124, 127, 130
primary care centers in, 16
priority-setting for treatments in, 378, 380, 385
quality of care in, 343
rheumatic heart disease in, 199, 201
South Asia. See also specific countries
cardiometabolic disease in, 39
cardiovascular, respiratory, and related disorders (CVRDs) in, 26, 28, 30
chronic respiratory diseases in, 264
community-based care in, 306
diabetes in, 211, 216, 220
heart failure in, 185
hypertension in, 390
ischemic heart disease in, 140–41
kidney disease in, 244–45
obesity/overweight in, 117
rheumatic heart disease in, 197
stroke in, 157
tobacco use in, 68–70
South-East Asia. See also specific countries
cardiometabolic disease in, 39
cardiovascular, respiratory, and related disorders (CVRDs) in, 26
chronic respiratory diseases in, 264
cost-effectiveness of interventions in, 350–51, 353, 359
diabetes in, 211
diabetes and, 219, 224
diet in, 107, 110
diet and nutrition in, 107, 110
dietary guidelines, 85
diabetes in, 213
ischemic heart disease and, 141–43, 145–46
peripheral artery disease and, 254
primary care centers and, 15
primary, 162–65
secondary, 166–67
self-management, 166–67
Sri Lanka, kidney disease in, 240, 241b
SSBs. See sugar and sugar-sweetened beverages
speech therapy, 168
sports systems and programs, 79–80, 85, 87–91
Spain
speech therapy, 168
Stevenson, C. R., 290
streptococcal pharyngitis, 197, 200–201
stroke, 157–72. See also ischemic stroke
burden of disease, 157–59
cardiometabolic disease and, 37
cardiovascular, respiratory, and related disorders (CVRDs) and, 23–24, 26–30
community-based care and, 309, 312
cost-effectiveness of interventions, 12, 356–58, 360, 369, 371–72
diabetes and, 160, 210–11, 214
diagnosis, 162
diet and, 103–4, 161
disability and, 158
echocardiography, 182
electrocardiography (ECG), 182
exercise capacity, 182
fibroblast growth factor 23 (FGF23), 145
high blood pressure, 182
heart failure, 182
hypertension and, 159, 390–91, 394–95, 397
ischemic heart disease and, 136–37
modifiable risk factors, 159–61
mortality and morbidity, 26, 27f, 157, 158m, 160, 162, 211, 389
obesity/overweight and, 161
peripheral artery disease and, 253–54
physical activity and, 82, 83–84, 86–87, 161
primary, 161–65, 179, 357
prevention, 161–65
primary care centers and, 15
priority-setting for treatments in, 382
quality of care and, 333, 336, 341
risk factors, 28–29, 65, 70, 83, 159–60r, 159–61, 163–64
self-management, 166–67
sodium reduction, 163
strokes, 157–72
tobacco use reduction, 162
primary care centers and, 15
quality of care and, 333, 336, 341
risk factors, 28–29, 65, 70, 83, 159–60r, 159–61, 163–64
screening, 161–62
surveillance, 161
tobacco use and, 63–65, 67–68, 160, 162
treatment, 165–66
cognitive rehabilitation, 168
cost-effectiveness, 168
physical, occupational, or movement therapy, 168
rehabilitation, 167–68, 167–68
speech therapy, 168

Trendelenburg operation, 69
Trendelenburg test, 70

Tobacco use, 57–78
aortic artery disease and, 66
arrhythmia and, 66
cardiovascular, respiratory, and related disorders (CVRDs) and, 26, 28–30, 31–32
cardiovascular disease and health outcomes, 63–67, 64b, 64f
mortality rates, 64
pathophysiology and mechanisms, 58–62, 59–60f
risk factors, 62–63
carotid and cerebrovascular diseases and, 65
cessation benefits, 69–70, 70b
chronic kidney disease and, 66–67
chronic respiratory diseases and, 265, 271
community-based care and, 308
coronary heart disease and, 65
cost-effectiveness of interventions, 350–52, 351t, 353, 355, 360, 370–71, 370t
diabetes and, 63, 210, 215
diet and, 110
dyslipidemia and, 62
forms of, 67t, 68–69
tissue plasminogen activator (tPA), 165

Tanzania
cost-effectiveness of interventions in, 369
health care costs in, 8
kidney disease in, 237b, 238–39

task-shifting
community-based health care, 305–12, 307–9t, 311b
patient-provider-level interventions, 341, 343
taxation
of tobacco use, 9, 13, 16, 144–45, 162, 350–52, 355, 372–73
of unhealthy beverages and foods, 11–12, 108–9, 124

telemedicine, 315
television watching, 79, 106, 120–21, 125, 127–28

Thailand
community-based care in, 316
ischemic heart disease in, 141, 144–45
kidney disease in, 245, 247
obesity/overweight in, 125
primary care centers in, 15
priority-setting for treatments in, 375, 378
stroke in, 163, 167–68

Thai Registry in Acute Coronary Syndrome (TRACS), 143

thirdhand smoke, 67–68

Thomas, Bernadette, 235
thrombolysis, 143, 254, 329, 333, 360
thrombosis, 60–61, 164

Tiotropium, 272

Thermoregulation, 58b

Thrombosis, 60–61, 164

Thomson Reuters, 102

Tobacco
aortic artery disease and, 66
arrhythmia and, 66
cardiovascular, respiratory, and related disorders (CVRDs) and, 26, 28–30, 31–32
cardiovascular disease and health outcomes, 63–67, 64b, 64f
mortality rates, 64
pathophysiology and mechanisms, 58–62, 59–60f
risk factors, 62–63
carotid and cerebrovascular diseases and, 65
cessation benefits, 69–70, 70b
chronic kidney disease and, 66–67
chronic respiratory diseases and, 265, 271
community-based care and, 308
coronary heart disease and, 65
cost-effectiveness of interventions, 350–52, 351t, 353, 355, 360, 370–71, 370t
diabetes and, 63, 210, 215
diet and, 110
dyslipidemia and, 62
forms of, 67t, 68–69

tissue plasminogen activator (tPA), 165
global mandate for reducing, 57–58
health consequences of, 351
heart failure and, 65
hypertension and, 62–63, 397
ischemic heart disease and, 142, 143–45
maternal smoking and cardiometabolic disease, 39, 44
obesity/overweight and, 130
peripheral artery disease and, 66, 255–56
secondhand smoke, 67
smoking cessation, 62, 144, 221, 224, 258, 263, 265, 336, 391
socioeconomic variables, 69
stroke and, 65, 159–60, 162, 169
taxation of, 9, 13, 16, 144–45, 162, 350–52, 355, 372–73
thirdhand smoke, 67–68
TRACS (Thai Registry in Acute Coronary Syndrome), 143
Training Programme for Caregivers of Inpatients after Stroke, 167
trans fats consumption, 14, 102, 104, 106, 108, 353–54
transportation systems design, 89
treatment
congenital heart disease (CHD), 194–95
cost-effectiveness, 195–96
diabetes and, 264, 267–69, 275
cost-effectiveness of interventions, 371
diabetes and, 288–92, 289f, 290–91r
tuberculosis
cost-effectiveness of interventions, 371
diabetes and, 288–92, 289f, 290–91r
integrated care and, 287–92, 294
integrated care in, 131
kidney disease and, 244
prioritization for treatments in, 378–81
prioritization for treatments in
rheumatic heart disease in, 199
stroke in, 159, 164
universal health coverage (UHC), 4, 16–17, 23, 344–45, 369, 371–72, 376, 385
University of Colorado at Denver, 241b
urban planning and design, 89, 120, 126
Uruguay
ischemic heart disease in, 144
kidney disease in, 244
priority-setting for treatments in, 384
V
Vaca, Claudia, 375
Vaidyanathan, B., 191
van Pelt, Maurits, 321
Vedanthan, Rajesh, 327
vegetables, 13, 28, 32–33, 103–8, 124–26, 129, 131, 160–62, 169, 266
Venezuela, República Bolivariana de
insulin costs in, 10
priority-setting for treatments in, 378
Verguet, Stéphane, 369
Vietnam
chronic respiratory diseases in, 264
congenital heart disease in, 194
cost-effectiveness of interventions in, 11, 351, 360
tobacco use in, 68

W
waterpipe smoking, 68
Watkins, David A., 1, 23, 191, 201, 202, 369
Webb, Michael, 101
Weber, Mary Beth, 305
weight. See birth weight; body mass index; obesity/
overweight
weight-loss diets, 126
Whitsel, Laurie, 101
WHO. See World Health Organization
WHO Choosing Interventions that are
Cost-Effective (WHO-CHOICE), 110
WHO Study on Prevention of Recurrences
of Myocardial Infarction and Stroke
(WHO-PREMISE), 145
Will, J. C., 63
women. See gender issues; pregnancy
Wong, Gary, 263
worksite interventions, 105, 129–30
World Health Assembly, 57
World Health Organization (WHO)
on cardiovascular, respiratory, and related
disorders (CVRDs), 23–31
on chronic respiratory diseases, 277–78
on community-based care, 308–11
on congenital heart disease, 191–92
on cost-effectiveness of interventions, 13–15, 353–57, 369–70
on diabetes, 211
on diet and nutrition, 107–9
on heart failure, 174–75, 182b
on hypertension, 390–91, 396–97
on integrated care, 288–90
on ischemic heart disease, 145
on obesity interventions, 117–18, 129–30, 130
on physical activity, 79–81, 92
on priority-setting for treatments, 376–79
on rheumatic heart disease, 197–201
on tobacco use, 57
World Medical Association, 311
Wu, Yangfeng, 1, 157

Y
Yan, Lijing L., 157
Yancy, Clyde W., 173
Yeates, Karen, 237b

Z
Zhang, Ping, 209
Zhao, Dong, 157
Zhu, Yishan, 157